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Associations of cardiovascular risk factors, cognitive performance, and
depressive symptoms have been well established. However, the directionality of these
associations as well as the specificity of these associations with respect to executive
function are less clear. Additionally few studies have determined whether genetic risk
factors, such as apolipoprotein-E4 (APOE-E4) genotype, and age moderate the
associations of cardiovascular risk factors such as homocysteine with changes in
depressive symptoms and how these associations may be mediated by cognitive
performance. The primary aim of this study was to analyze the bidirectional
associations of a full range of cognitive domains and symptoms of depression over a
period of 5 years and to determine the extent to which the conditional associations of
homocysteine (moderated by age and APOE-E4 genotype) and changes in depressive
symptoms are mediated by cognitive performance. Additionally, we aimed to determine
the extent to which these associations are specific to executive function as compared

with other domains of cognitive function. After exclusions for probable dementia, kidney
dialysis, and acute stroke, 719 adult participants were available for analysis for the sixth
and seventh waves of the Maine-Syracuse Longitudinal Study. We conducted crosssectional multiple linear regression analyses and cross-lagged panel analyses (CLPD)
to determine the strength and directionality of associations for cognitive function and
symptoms of depression. Next, we conducted conditional mediation path analyses to
explore the associations of homocysteine (moderated by age and APOE-E4) and
changes in self-reported depressive symptoms as mediated by cognitive function. All
models were adjusted for wave 6 demographic covariates (age, sex, education,
ethnicity, and marital status), cardiovascular risk profile (Framingham Risk Score), and
depressive symptoms. In fully adjusted cross-sectional models, depressive symptoms
were inversely associated with executive function and several other cognitive domains.
In CLPD, cognitive performance was a stronger and more consistent predictor of
changes in depressive symptoms (Executive Function, Global performance, Scanning
and Tracking, and Visual-Spatial Organization and Memory) than depressive symptoms
were of changes in performance. Although cognitive performance largely did not
mediate the associations of cardiovascular risk factors (homocysteine and Framingham
Risk Score) and changes in depressive symptoms, we did observe direct associations
of Framingham Risk Score and changes in symptoms as well as significant moderation
by age and APOE-E4 for the associations of homocysteine and changes in depressive
symptoms. For APOE-E4 non-carriers, higher homocysteine was associated with
symptom increases for individuals ≥ 74.33 years of age and for APOE-E4 carriers, there
were marginal risks for individuals ≤ 45 years of age. The findings of this study have

important clinical implications in assessing risk for and prevention of depressive
symptoms both via maintenance of cognitive function and CVD risk reduction. Better
executive functioning and performance in other cognitive domains was associated with
lower levels of depressive symptoms over five years. Lower levels of CVD risk, both for
the well-established CVD risk factors indexed by the Framingham Risk Score and for
homocysteine, were associated with lower levels of depressive symptoms over five
years. Moderation of depressive symptoms may be afforded through interventions
designed to maintain executive function and to reduce risk relating to modifiable CVD
risk factors such as homocysteine. Clinical trials with patient populations are needed to
determine whether modification of homocysteine via dietary or physical activity
adjustments could provide effective prevention of depressive symptoms.
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1. INTRODUCTION
Human cognitive and emotional development is rapid in early life, but it is well
known that changes continue to occur throughout adulthood and into later life. One
influential cognitive aging model distinguishes between total fund of world knowledge
(i.e., crystalized), which tends to remain stable in older adulthood and abilities relating to
speed and power of decision-making (i.e., fluid), which tends to decline with aging
(Glisky, 2007; Harada, Natelson Love, & Triebel, 2013; Horn & Cattell, 1967). It is also
well known that cognition and emotion regulation have considerable overlap at every
age (Hammar & Ardal, 2009). Successfully coping with novel events and stressors
requires both the ability to regulate emotion and the ability to select, plan, initiate, and
reevaluate appropriate behavioral actions. However, despite some overlap between
cognitive ability and depressive symptoms, not all individuals with high levels of
depressive symptoms have low cognitive ability and not all of those with low cognitive
ability experience high levels of depressive symptoms, which have led many
researchers to examine what risk factors may be common to both conditions.
Interest continues to grow with regard to the vascular risk factors that are
common among older individuals with cognitive deficits and depressive symptoms and
there is an expanding literature on the possibility that vascular mechanisms underlie the
relationships between cognitive decline and depressive symptoms. Prevention and
reduction of vascular risks through lifestyle changes and pharmacological treatment
may not only reduce the medical burden posed by cognitive decline and symptoms of
depression, but may also result in a lifespan compression of overall morbidity and
dependent/institutional living.
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In Section 1.1, we review different measurements of depressive symptoms
(Section 1.1.1), depressive symptoms and aging (Section 1.1.2) and the vascular
depression hypothesis (Alexopoulos et al., 1997; Section 1.1.3). In Section 1.2, we
highlight two vascular risk factors of interest: homocysteine (Section 1.2.1) and
Apolipoprotein E genotype (Section 1.2.2).
In Section 1.3 we discuss the measurement and course of cognitive performance
and the prevalence of cognitive impairment (Section 1.3.1) and its relationship with
executive function, vascular disease, and homocysteine (Sections 1.3.2 to 1.3.4). We
then discuss how executive function, aging, and symptoms of depression may be
related (Section 1.4) by summarizing the literature on depression-executive dysfunction
syndrome (Section 1.4.1) and, possible directional associations of depressive
symptoms and cognitive performance/executive function. We close chapter 1 by
proposing possible mechanisms of cognitive decline (1.4.2 to 1.4.3).
In this study, we first aim to expand upon the vascular depression hypothesis by
observing how performance across several cognitive domains may predict changes in
depressive symptoms over time. After exploring the temporal connection between
cognitive performance and depressive symptoms, we analyze whether cardiovascular
risk factors such as age, APOE-E4 genotype, and homocysteine interact to predict
changes in symptoms of depression through their associations with cognitive
performance.
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1.1 Symptoms of Depression
Episodes of major depression are characterized by a wide range of persistent
affective, behavioral, and cognitive symptoms. There are two main competing
diagnostic systems currently in use, the World Health Organization’s International
Classification of Diseases (ICD-10; WHO, 2016) and the American Psychiatric
Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA,
2013). Although there is some difference with regard to the specific word choice for
describing diagnostic criterion, the DSM-5 and the ICD-10 overlap considerably
regarding the diagnosis of an episode of Major Depressive Disorder (MDD).
Specifically, MDD is characterized by persistent dysphoria and loss of interest/pleasure
in daily activities and may include any of the following symptoms: disturbance in
sleep/weight/appetite/psychomotor activity, fatigue, feelings of guilt/worthlessness,
diminished ability to concentrate or make decisions, and thoughts of suicide. In both the
ICD-10 and DSM-5, individuals with MDD may be further subdivided into Mild, Moderate
or Severe categories based on symptom count and severity, but they are ultimately
categorical taxonomies. These systems provide useful heuristics for binary treatment
decision-making, but evidence from community-based population studies suggests that
unipolar depression is more likely to be a dimensional construct with a continuum of
related symptoms found among all individuals (Prisciandaro & Roberts, 2005). This is
important because individuals often experience similar levels of functional impairment
despite being just below a diagnostic threshold (Prisciandaro & Roberts, 2005). The
next section will discuss both the diagnostic prevalence of MDD as well as the
phenomenology of symptoms of depression in older compared with younger adults.
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1.1.1 Symptoms of Depression and Aging
MDD is one of the most common mental health disorders in the United States. In
2014, approximately 15.7 million adults (6.7%) experienced at least one Major
Depressive Episode (MDE) in the past 12 months. Compared with younger (9.3%) and
middle-aged adults (7.2%), older adults (5.2%) are estimated to have a lower 12-month
prevalence rate of MDE (Center for Behavioral Health Statistics and Quality, 2015).
However, lower estimates of MDD among older adults may be systematically biased by
the association between MDD and early mortality (Blazer, 2009). Additionally, older
adults (≥ 65y) are less likely to identify a range of symptoms of depression (i.e.,
sadness, guilt, thoughts of suicide, motor slowing, trouble concentrating, and insomnia)
compared with younger adults (< 65y; Wetherell et al., 2009). Current diagnostic
systems also prioritize dysphoria which is less commonly endorsed by older adults
compared with younger adults (Hegeman et al., 2012).
However, despite a general decreasing trend for depressive symptoms in the
transition from middle to later adulthood, older adults are at an increased risk for
experiencing a number of conditions associated with depression. For example,
symptoms of depression are common among those recovering from myocardial
infarction, stroke, and hip fractures or suffering from diabetes, arthritis, and kidney
disease (Blazer, 2009). Additionally, institutional living, lack of social support,
bereavement, functional impairment and loss of economic power are also more
common, especially among the oldest old and contribute a significant level of risk for
depressive symptoms (Blazer, Burchett, Service, & George, 1991; McDougall,
Matthews, Kvaal, Dewey, & Brayne, 2007). Sleep disturbance, subjective memory
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complaints, fatigue, and motor slowing, which are more common among depressed
older adults, may be misconstrued as conditions associated with normal aging,
medication use, or general medical ailments (Fiske, Wetherell, & Gatz, 2009).
Although the risk for future depressive episodes is considerably greater for those
with a history of MDD (Burcusa & Iacono, 2007), as many as half of older adults with
MDD experience the condition as a first episode (Brodaty et al., 2001). Most studies
define “late-onset depression” as experiencing an initial depressive episode after the
ages of 50 – 65 (Blazer, 2009; Driscoll et al., 2005; Fountoulakis et al., 2003;
Mahapatra, Sharma, & Khandelwal, 2015). Evidence suggests that among older adults,
those with early or late-onset depression exhibit similar levels of severity and diagnostic
phenotypes; however, late-onset depression appears to be less associated with family
history of mood disorders and pre-morbid personality abnormalities and more
associated with recent stressful events (Brodaty et al., 2001; Bukh, Bock, Vinberg,
Gether, & Kessing, 2011; Burcusa & Iacono, 2007). This suggests that although the
phenomenology of early and late-onset depression among older adults may be similar,
they may result from different etiological factors. Investigations of these pathways have
focused on age-related risk factors associated with structural and functional changes in
the brain among older adults.
1.1.2 Vascular Depression
The vascular depression hypothesis was coined by Alexopoulos et al. (1997),
following case observations of older adult patients suffering from depression. They
proposed that cerebrovascular disease may predispose or exacerbate symptoms of
depression via disruption of frontostriatal circuits responsible for emotion regulation and
5

executive function (discussed later). Evidence for the vascular depression hypothesis
can be found in the high level of observed comorbidity between symptoms of
depression and vascular disease. In one analysis, 53% and 42% of patients (N = 106,
age range 19-82y) were diagnosed with major or minor depression 3 and 6 months
respectively following an ischemic stroke (Kauhanen et al., 1999), which is the result of
severe restriction or blockage of cerebral blood flow. Stroke may be one of the most
acute vascular events associated with altered brain functioning, but evidence also
suggests that more silent, but chronic conditions and markers of vascular disease may
be associated with symptoms of depression in late life among those without history of
stroke or major vascular event.
Magnetic resonance imaging (MRI) studies have allowed researchers to observe
the associations of less severe, but none-the-less damaging small vessel diseases with
depressive symptoms among older adults. Several MRI studies of depressed patients
have shown greater volume of ischemic white matter lesions (shown as white matter
hyperintensities, WMH) and lower neuronal density compared with age matched
controls, particularly in the dorsolateral prefrontal cortex, orbitofrontal cortex, and in the
caudate nucleus (Firbank, Llyod, Ferrier, & O’Brien, 2004; Khundakar, Morris, Oakley, &
Thomas, 2011; W. D. Taylor et al., 2007; Thomas et al., 2002). Additionally, after
adjustment for baseline depressive symptoms and cardiovascular risk factors, WMH
volume, increases in subcortical infarcts, and decreases in brain volume have predicted
depressive symptoms severity in 3-5 year prospective analyses among community
dwelling older adults (Firbank et al., 2004; Godin et al., 2008; van Sloten et al., 2015).
Although there is not yet a consensus on whether vascular depression represents a
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distinct clinical subtype of depression (Sneed & Culang-Reinlieb, 2011), researchers are
increasingly looking towards the possibility that various vascular risk factors may place
some individuals at a higher risk for depressive symptoms later in life.
1.2 Vascular Risk Factors: Homocysteine and Apolipoprotein Genotype
The major vascular risk factors emphasized in this study are homocysteine and
apolipoprotein genotype. In the sections that follow, the literature on each will be briefly
discussed with regard to their vascular risk status and associations with cognitive
performance and depressive symptoms.
1.2.1 Homocysteine
Homocysteine (Hcy) is a sulfur amino acid metabolite biosynthesized from
ingested methionine found in many dietary proteins. Methionine, via its conversion to Sadenosyltransferase is essential in the stabilization of proteins including myelin and is
also involved in the synthesis of melatonin, norepinephrine, and in the metabolism of
serotonin. Normally, in concert with the folate (B9) cycle, Hcy is either converted back
into methionine by cofactor cobalamin (B12) via re-methylation or converted to cysteine
and taurine by pyriodoxine (B6) via trans-sulfuration (Ganguly & Alam, 2015; Refsum et
al., 2004). Low dietary intake or absorption of B-vitamin cofactors are among the most
common causes for elevated Hcy, defined as >15 µmol/L for adults aged 15-65 years of
age (>12 µmol/L folic acid supplemented) and >20 µmol/L for adults >65 years of age
(>16 µmol/L folic acid supplemented; Refsum et al., 2004). In addition to age, male
gender, menopause, impaired renal function, and genetic factors (see section 1.2.2 for
discussion of Apolipoprotein-E allele), several lifestyle factors have been associated
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with high levels of Hcy including smoking, coffee and alcohol intake (Elias et al., 2008;
Refsum et al., 2004).
1.2.1.1 Homocysteine and Cardiovascular Disease
Although some elevation of Hcy is typical in older age, high levels of Hcy through
imbalances in production or elimination can cause oxidative stress, amyloid beta
concentrations, plaque deposition, DNA strand breakage, and in turn apoptosis (Fuso et
al., 2008). Additionally, high levels of Hcy can result in damage to endothelial cells and
inflammation of blood vessels which can lead to atherogenesis and in turn
cerebrovascular ischemia (Ganguly & Alam, 2015).
Despite the wellspring of recent research interest in Hcy, early evidence from
case reports stretches back several decades. Observations from early archival case
studies in the 1930’s revealed an association between a genetically inherited inability to
metabolize methionine, homocystinuria (high levels of urine homocysteine), and
vascular insults among very young children and infants (Shih & Efron, 1970). Additional
case studies in the 1950’s and 1960’s showed that in the most severe cases of
homocystinuria, children experienced pronounced cognitive deficits, thromboembolic
disease, and early death (Carmel & Jacobson, 2002). McCulley observed that despite
having different enzymatic etiologies, many of these cases of homocystinuria also had
advanced and widespread plaque buildup in major arteries resulting in arteriosclerosis
(McCully, 2007). These observational studies were further supported by the
experimental work of Mann et al. (1953), which showed that atherosclerosis and
vascular lesions could be induced in Cebus monkeys with controlled variations of
dietary sulfur amino acids.
8

Since these early clinical studies, large epidemiological studies have provided
additional support for the link between cardiovascular disease and high levels of
homocysteine. In a meta-analysis of 27 cross-sectional, case-control, and prospective
studies, Boushey (1995) found that with every 5 μmol/L increase of total plasma
homocysteine (tHcy) there was a 50% increase in cerebrovascular disease and
estimated that 10% of coronary artery disease risk can be attributed to high tHcy.
Additionally, Vollset et al. (2001) observed a dose-response relationship between higher
levels of tHcy and all-cause mortality risk among adults 40-67 years of age (average
follow-up 4.1 years), particularly among individuals with high risk for cardiovascular
disease (CVD).
These findings have been further supported by experimental epidemiology
analysis. A United States and Canadian population study observing the effect of folic
acid fortification of enriched grain products from 1998-2002 showed increases in
average blood folate concentrations, reductions in plasma total homocysteine (tHcy),
and significant incremental decreases in stroke mortality compared with the preenrichment period (1990-1997), even with adjustment for societal level changes in
known cardiovascular risk factors such as cigarette smoking, hypertension, diabetes,
and high total serum cholesterol (concentration ≥240 mg/dl). Interestingly, this
prevalence rate decline was not found in England and Wales where folate fortification
was not required (Yang et al., 2006).
1.2.1.2 Homocysteine and Depressive Symptoms
Among other well-recognized cardiovascular risk factors, high levels of Hcy have
also been a target of interest in the development of affective disorders, particularly in
9

later life. Much of the research on Hcy and depressive symptoms has been crosssectional. Almeida et al. (2008) conducted a meta-analysis of 9 observational studies
mainly consisting of older community-dwelling adults (N = 7,114) as well as data from
the Health in Men Study (N = 4,245). Of the 9 total studies included for analysis, 6
showed positive associations between tHcy and clinically significant levels of depressive
symptoms (i.e., > survey cut score thresholds) or diagnosed major/minor depression
(Almeida et al., 2005, 2008; Bjelland et al., 2003; Bottiglieri et al., 2000; Cassidy et al.,
2004; Tolmunen et al., 2004). In all, Almeida et al. estimated that those with high levels
of tHcy were 70% (95% CI: 1.38-2.08) more likely to have clinically significant levels of
depressive symptoms compared those with lower levels of tHcy after adjusting for a
range of medical comorbidities and cardiovascular risk factors. However, two crosssectional studies in this analysis failed to find an association between high levels of tHcy
and clinically significant levels of depressive symptoms. Penninx et al. (2000) failed to
find any association in a sample of disabled women (>=65y) and Tiemeier et al. (2002)
did find an initial association between depression status and high tHcy, but this
association was non-significant when adjusting for cardiovascular disease. Although
these cross-sectional results are promising, longitudinal research is necessary to
determine whether Hcy contributes as a potential risk factor for depressive symptoms
over time rather than just being associated with depressive symptomatology.
Few prospective studies have been conducted, but results have been generally
supportive of higher baseline tHcy predicting clinically significant levels of depressive
symptoms at 4-year follow-up in women (Forti et al., 2010) and in men (combined
baseline/followup risk; Tolmunen et al., 2004). In one Korean sample, which excluded
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baseline depression and adjusted for age, gender, education, Mini Mental State Exam
(MMSE; Folstein, Folstein, & McHugh PR, 1975), disability, smoking, problem drinking,
physical activity, and vascular risk, decreases in B12/B9 and increases in tHcy over a
follow-up period of 2.4 years all predicted increased depression incidence (Kim et al.,
2008).
1.2.2 Apolipoprotein-E4 Genotype
Genetic factors relating to vascular function may moderate the relationship
between tHcy and vascular depression. The apolipoprotein (APOE) gene provides
information necessary for the synthesis of the APOE-E protein. This protein binds to
lipids creating lipoproteins, which are responsible for packaging and carrying cholesterol
and other fats through the blood stream. Carriers of at least one APOE-E4 allele have
been shown to have significantly higher rates of CVD and cognitive
impairment/dementia (Eichner, 2002; Small, Rosnick, Fratiglioni, & Backman, 2004) and
previous cross-sectional studies from the Maine-Syracuse Longitudinal Study (MSLS)
have shown that carrying at least one APOE-E4 allele may multiply the risk associated
with higher tHcy for lower cognitive performance (Elias et al., 2008).
Although cross-sectional evidence for the association between depression and
the APOE-E4 allele has been mixed, most of the studies conducted thus far have
included small sample sizes, which may lack sufficient statistical power for detecting
group differences in complex regression models (Evans & Rajan, 2015). Additionally, a
recent 5 and 9-year prospective study of older adults has shown positive associations
between the APOE-E4 allele, depressive symptoms, and late life minor depression
incidence (Skoog et al., 2015). Another 1-year prospective study found no difference
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between depressed and non-depressed older adults with regard to cognitive decline,
but significant differences in decline when comparing depressed and non-depressed
individuals carrying the APOE-E4 allele (Niti, Yap, Kua, & Ng, 2009). It is unclear if the
APOE-E4 allele affects the directional association between executive function and
depressive symptoms, but it is possible that failing to account for APOE genotype may
explain previously negative findings in studies using relatively invariant outcome
measures (i.e., depression diagnosis, MMSE).
1.3 Cognitive Performance
Like depression, cognitive performance can be considered a unitary construct or
one made of up several associated factors. Cognitive performance in this context can
also be measured as a categorical-clinical construct or as a continuum of ability ranging
from low to high. Dementia is the most severe level of cognitive deficit with mild
cognitive impairment (MCI) being considered an intermediate stage of decline from
normal functioning (Petersen et al., 2001). Broadly defined, MCI is cognitive decline
which is greater than would be expected for an individual’s age or education level (often
at least 1.5 standard deviations), but does not interfere with one’s ability to live
independently as is seen in the case of dementia (Abner et al., 2012). The decision to
diagnose dementia (National Institute of Health, 2013) or MCI is often based on
professional agreement derived from patient/ caregiver interview and cognitive testing.
Importantly, these are clinical definitions of severity rather than etiology of cognitive
decline, which is quite heterogeneous. The most common conditions associated with
dementia are Alzheimer’s disease (AD) followed by, Vascular Dementia (VaD),
Frontotemporal Dementia (FTD), Synucleinopathies, and Huntington’s Disease
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(National Institute of Health, 2013). Although cognitive performance is often considered
a continuous construct, MCI and dementia as clinical constructs can provide caregivers
and researchers with a common language to understand the scope of the problem of
cognitive decline among older adults.
1.3.1 Prevalence and Course of Cognitive Impairment
There are upwards of 24.3 million adults living with dementia world-wide and the
number of individuals with dementia is expected to rise to 81.1 million by 2040 (Ferri et
al., 2005). The average age of the U.S. population continues to rise as individuals are
able to live longer and as such so does the burden of cognitive impairment (Ortman,
Velkoff, & Hogan, 2014). Currently 3-21% of individuals over the age of 65 in the U.S.
are estimated to have MCI and roughly half of these individuals go on to develop
dementia within five years of initial diagnosis (Gauthier et al., 2006; Manly et al., 2008;
Petersen et al., 2001).
Aging and the transition from normal functioning to MCI may impact several
cognitive domains, but some aspects of cognitive functioning are more likely to be
impacted by the aging process. Evidence is broadly consistent with Cattell and Horn’s
(1967) crystalized-fluid model of aging. Older adults tend to experience the greatest
declines in domains associated with novel problem solving (i.e., executive function,
working memory, processing speed, and perceptual reasoning) compared with
performance associated with total fund of knowledge and overlearned skills (Glisky,
2007; Harada et al., 2013). While significant declines in any cognitive domain may be
problematic, recent research has highlighted the particularly important role of executive
function in maintaining functional independence.
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1.3.2 Cognitive Impairment and Executive Function
Although researchers vigorously debate how to operationalize the construct of
executive function, a general consensus on its definition has existed since its first
introduction in Baddeley and Hitch’s model of working memory (1974). Broadly
speaking, executive function is a set of high-order mental processes that involve
response inhibition, working memory, and mental flexibility (Alvarez & Emory, 2006;
Diamond, 2014). These core executive functions form the basis for planning and
decision-making, troubleshooting and adapting to novel situations, and effortful
inhibition of habitual behaviors (Jurado & Rosselli, 2007). Significant deficits in
executive function have been observed among older adults with MCI across clinical
subtypes (amnesic vs. non-amnesic and single vs. multiple domain; (Brandt et al., 2009;
Traykov et al., 2007; Zheng et al., 2012). Additionally, these declines may precede
disturbances in global functioning and memory and measures associated with executive
function have been shown to have incremental utility in predicting transition from normal
functioning to MCI/dementia (Carlson, Xue, Zhou, & Fried, 2009; Elias et al., 2000; J. K.
Johnson, Lui, & Yaffe, 2007; Ratcliff, Dodge, Birzescu, & Ganguli, 2003).
1.3.3 Cognitive Performance and Vascular Disease
The associations between cardiovascular disease and cognitive performance in
middle and later adulthood has been well established through a series of carefully
conducted observational studies following participants over the entire adult lifespan
(Elias, Goodell, & Dore, 2012; Framingham Heart Study, 2016). Much like depression,
individuals who have experienced acute vascular attacks such as stroke are at an
increased risk for cognitive impairment following the event. There is a considerable
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number of variables which affect the likelihood for cognitive impairment post-stroke, but
prevalence estimates range from 20 – 80% depending on age, race, and diagnostic
criteria being applied (Sun, Tan, & Yu, 2014). These strong associations led to the
recognition of vascular cognitive impairment/dementia, which has been expanded to
include impairment in the presence of more silent cerebral small vessel conditions such
as WMH and lacunar infarcts (Brickman et al., 2009; Vermeer et al., 2009). Other
studies have found consistent positive associations between total cardiovascular risk
factor load and poorer cognitive performance for visual-spatial memory, working
memory, processing speed, executive function, and global performance more generally
(Crichton, Elias, Davey, & Alkerwi, 2014; Reis et al., 2013; Sabia et al., 2009).
1.3.4 Cognitive Performance and Homocysteine
As a well-recognized cardiovascular risk factor, interest in the association
between Hcy, vascular disease, and cognitive performance has increased exponentially
since the mid-1960’s (Robinson, 2000). In cross-sectional analyses, tHcy level has
been observed to be inversely associated across multiple domains of cognitive
performance (Elias et al., 2005, 2006), and perhaps most strongly with processing
speed and executive function (Polito et al., 2016; West et al., 2011). Additionally, in 3
and 8-year prospective analysis, high baseline tHcy was found to be predictive of
conversion from normal cognitive functioning to MCI and dementia (Gabryelewicz et al.,
2007; Seshadri et al., 2009). Importantly, many of these findings were adjusted for a
range of demographic factors, comorbid cardiovascular disease, and psychiatric illness.
Individuals with vascular cognitive impairment also tend to have higher tHcy and lower
B12 and folate compared with either stroke patients without cognitive impairment or
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healthy controls, indicating an incremental cognitive risk with increasing levels of tHcy
(Jiang et al., 2014). For an extended literature review on homocysteine, vitamins, and
cognitive functioning see Crichton, Robbins, and Elias (2015).
Not all individuals experience similar lowering in cognitive functioning as a result
of high tHcy. There appears to be cross-sectional evidence for an interaction between
age and high tHcy. Specifically, the relationship between high tHcy and poor cognitive
function appears to be strongest among older adults (Agrawal et al., 2015; Elias et al.,
2005). Although many cardiovascular disease risk factors were statistically controlled in
these studies, Agrawal et al. (2015) speculate that high levels of Hcy are more likely to
co-occur in the presence of other aging related markers of vascular disease, which may
have a synergistic impact on cognitive decline.
1.4 Executive Function, Aging, and Symptoms of Depression
One possible mediator for the relationship between vascular risk factors such as
tHcy and depressive symptoms may be through deficits in cognitive performance and
more specifically deficits in executive function through vascular insult. In the next
sections, we discuss profiles of depression-executive dysfunction among older adults,
followed by a review of the literature on the directional associations of cognitive
performance and depressive symptoms and possible mechanisms of decline.
1.4.1 Depression-Executive Dysfunction Syndrome
There is consistent evidence that individuals experiencing the acute phase of
depression have lowered cognitive performance across multiple domains and ages (i.e.,
executive function, attention, memory, processing speed; Hammar & Ardal, 2009).
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Bipolar patients with high levels of tHcy tend to perform worse on the Verbal
Comprehension and Perceptual Organization subtests of the Wechsler Adult
Intelligence Scale – Revised (WAIS-R; Wechsler, 1981) and on the Stroop task,
particularly among men (Permoda-Osip, Kisielewski, Dorszewska, & Rybakowski,
2014). However, although depressed younger adults experience a range of deficits
compared with non-depressed peers, older depressed adults with poor vascular risk
profiles and both young and older adults who have experienced an ischemic stroke
experience significantly greater deficits in executive function, processing speed and gait
slowing/impairment compared with their non-depressed peers (Hajjar et al., 2009;
Lockwood, Alexopoulos, & van Gorp, 2002; Sanders, Bremmer, Comijs, Deeg, &
Beekman, 2016; Sobreiro et al., 2014), indicating possible interactions between aging,
vascular disease, and depression.
1.4.2 Directional Associations of Executive Function and Depressive Symptoms
It is important to determine the directionality between depressive symptoms and
cognitive impairment because this may provide caretakers and clinicians with
information for predicting disease trajectory. There is a small, but burgeoning literature
on the predictive value of low executive function and disruptions in frontostriatal
pathways and poor antidepressant treatment response among older adults, (Sheline et
al., 2010; Sneed et al., 2007; Tam & Lam, 2013). Additionally, if executive functioning is
predictive of future depressive symptoms, tests of executive functioning may be
considered for predicting risk of future episodes following treatment (Alexopoulos,
Kiosses, Klimstra, Kalayam, & Bruce, 2002). Even small reductions in the development
or severity of cognitive impairment or depressive symptoms through early detection,
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treatment, and monitoring could have considerable positive impacts at the population
level (Fiske et al., 2009; Zhu et al., 2013).
So far, only a few studies have systematically reviewed the reciprocal
relationship between depressive symptoms and cognitive functioning. One study
among older Hispanic adults (N = 194, Mean age = 78.5) examined this relationship
over a 3-year period using a structural equation modeling technique known as crosslagged panel analysis. In this study, the researchers measured global performance with
3 subtests (California Verbal Learning Test, Color Trails Test, Part 2, Fuld Object
Memory Evaluation) to represent short-term verbal learning, tracking, and short-term
object memory. They found that cognitive performance predicted subsequent
depressive symptoms (CES-D), but that depressive symptoms did not predict
subsequent cognitive performance when controlling for age, gender, and financial strain
(Perrino, Mason, Brown, Spokane, & Szapocznik, 2008). Given that this analysis was
restricted to advanced-aged adults; it remains unclear if these findings can be
generalized beyond later-life cognitive decline. In addition, this study did not specifically
analyze executive function outcomes (aside from inclusion in the composite) or
adjustment for vascular risk factors which may underlie the association between
cognitive performance and depressive symptoms in later life.
In another 2-year cross-lagged panel design of older adult (=> 65) primary care
patients (N = 284), Cui, Lyness, Tu, King, and Caine (2007) found the opposite results.
Depression diagnosis predicted subsequent executive function performance (Trails B
and Trails B-A), but executive function did not predict depression diagnosis. Sensitivity
analysis revealed similar results when including both subjects with dementia and those
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with a history of non-late onset depression. Additionally, they rescored the Hamilton
Depression Rating Scale (Hedlund & Viewig, 1979) to exclude vegetative symptoms
assumed to be epiphenomena of vascular depression (i.e., decreased activities/ libido,
gastrointestinal symptoms, weight loss, insomnia, psychomotor retardation, agitation,
diurnal variation, and other somatic symptoms) and found similar results, indicating a
more general longitudinal relationship between depression and executive function,
particularly in set shifting and response inhibition. Major strengths of this study were the
inclusion of adjustments for chronic illness and vascular disease and the measurement
of executive function outcomes. However, Cui et al. failed to account for error
covariance at baseline between depression and executive functioning, so it is unclear if
depression diagnosis actually predicted lowered executive functioning, or if depression
was just a concurrent risk in the presence of low executive function, and continued risk
for poor executive function 2-years later. Additionally, attrition (approx. 60%) was
considerably high, with non-completers more likely to have low scores on the
initiation/perseveration subscale of the Mattis Dementia Rating Scale. This likely
reduced the ability of Cui et al. to detect variation in depressive symptoms over time as
a result of cognitive dysfunction. Moreover, Cui et al. used multinomial logit regression
for predicting depression diagnosis (i.e., major, minor, none) which may have further
reduced their ability to detect subtle changes in depressive symptoms in comparison to
the use of continuous depressive symptom scores.
Lastly, a 2-year analysis of Korean community members (Yoon, 2014; Age > 65,
N = 3,511), revealed that both cognitive performance (measured by Korean-Mini Mental
State Exam) and depressive symptoms (CES-D Korean version) were negatively
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associated in lagged analysis, indicating a possible reciprocal relationship. The
significant bidirectional results of Yoon’s analysis may be a reflection of adequate
sample size to detect both causal pathways; however, their observed associations were
also modest. Additionally, Yoon did not include any adjustment for cardiovascular
disease. While the MMSE is an adequate screening measure for dementia, it is not
designed to detect subtle variations in executive function, which may be early indicators
for depression and cognitive impairment compared with recall (Juby, Tench, & Baker,
2002).
To our knowledge there has been no study to date that has systematically
explored these relationships over longer periods of time and across a wide range of age
groups. This is a particularly salient issue given the long latency period for cognitive
impairment and the potential benefits for early prediction of risks to independent living.
It is possible that the longitudinal relationship between executive function and
depressive symptoms change over the lifespan, becoming more strongly associated in
older adulthood in the presence of greater allostatic load and vascular impairment
(Lockwood et al., 2002). Additionally, no study to date has explored the mediating role
of executive function between tHcy and depressive symptoms.
1.4.3 Possible Mechanisms of Decline
It is possible that prolonged exposure to high tHcy results in cerebral
hypoperfusion and WMH which impairs executive functioning. Both loss of perceived
(Lawrence, Roy, Harikrishnan, Yu, & Dabbous, 2013) and actual cognitive ability could
explain the link between low executive function and future risk for depressive symptoms
among older adults. In general, depressed individuals tend to generate fewer and less
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appropriate problem-solving strategies under cognitive load (Channon & Green, 1999).
Poor executive function has also been associated with avoidant coping strategies
among stroke survivors (Kegel, Dux, & Macko, 2014) which may increase the risk for
future depressive episodes.
It is also plausible that depression is an independent risk factor for high tHcy and
subsequent executive dysfunction. Among women 20-34 years of age (N = 5,051)
depressive symptoms predicted both concurrent and subsequent lower folate levels
over a two year period. However, folate did not predict future depression (Kendrick et
al., 2008). Stressful life events may increase the risk for symptoms of depression such
as lower physical activity and dietary disturbance which may increase risk for high tHcy
(Okura et al., 2006; Rahman et al., 2013), poor vascular functioning, and subsequent
executive dysfunction. Additionally, several longitudinal analyses reviewed by Hammar
and Ardal (2009) concluded that executive function and processing speed dysfunctions
are not limited to depressive episodes. These impairments tend to persist during
symptom remission, reflecting a possible cognitive scarring effect of depression
(Burcusa & Iacono, 2007; Gorwood, Richard-Devantoy, Baylé, & Cléry-Melun, 2014).
However, none of these analyses accounted for cognitive performance prior to
experiencing a depressive episode, so it is yet unclear whether depressive episodes
represent a true risk for executive decline or if poorer executive functioning is simply a
characteristic of those more likely to experience depressive episodes and is relatively
invariant with regard to changes in clinical categorization. Lastly, it is possible that tHcy
represents a secondary marker for cerebral vascular disease rather than an
independent cause (Wierzbicki, 2007) and variations in cognitive function and
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depressive symptoms may be explained by already well-established vascular risk
factors.
1.5 Study Hypotheses in Relation to Objectives
No studies to our knowledge have: 1) analyzed the bidirectional associations of
depressive symptoms and executive function in the context of a full range of other
cognitive domains; or 2) investigated the extent to which age and APOE-E4 genotype
moderate the prospective associations of homocysteine and depressive symptoms and
the extent to which executive function mediates the prospective associations of
homocysteine and depressive symptoms.
Objectives of the proposed work with respective hypotheses were as follows:
1.

To examine the cross-sectional (at wave 6) associations of executive function

and depressive symptoms.
Hypothesis: Executive function will be associated with depressive symptoms at wave 6.
2.

To examine the cross-lagged prospective associations (wave 6 to wave 7) of

executive function with depressive symptoms.
Hypothesis: The strength of associations of wave 6 executive function and wave 7
depressive symptoms (adjusted for wave 6 depressive symptoms) will be stronger
compared with the strength of associations of wave 6 depressive symptoms and wave 7
executive function (adjusted for wave 6 cognitive function).
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3.

To determine whether age and APOE-E4 genotype (wave 6) moderate the

prospective associations of homocysteine (wave 6) and depressive symptoms (wave 7,
adjusted for wave 6 symptoms).
Hypothesis: APOE-E4 genotype and age will moderate the associations of wave 6
homocysteine and wave 7 depressive symptoms. Specifically, among those with higher
homocysteine, older adults who are APOE-E4 carriers will experience the greatest
increases in depressive symptoms.
4.

To determine the extent to which executive function mediates the associations of

the age x APOE-E4 x homocysteine interaction (wave 6) and depressive symptoms
(wave 7, adjusted for wave 6 symptoms).
Hypothesis: Wave 6 executive function will mediate the conditional association of the
age x APOE-E4 x homocysteine interaction (wave 6) and depressive symptoms (wave
7, adjusted for wave 6 symptoms), such that significant indirect conditional paths will be
observed for this interaction on increases in depressive symptoms through executive
function.
5.

To determine the specificity of the associations between executive function,

depressive symptoms, and the above CVD-RF’s in the context of a full range of
cognitive domains.
Hypothesis: The associations of executive function, depressive symptoms, and the
above CVD-RF’s will be similar across a broad range of cognitive domains.
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2. METHODS
2.1 The Maine-Syracuse Longitudinal Study Design
Since its inception in 1974, the Maine Syracuse Longitudinal Study (MSLS) has
studied the relationships between cardiovascular health and cognitive functioning for
over three decades. The original studies were primarily concerned with the effects of
idiopathic and uncomplicated hypertension on cognitive functioning and have since
expanded dramatically to include several other cardiovascular risk factors such as tHcy,
arterial stiffness, diabetes, cholesterol, kidney function, physical activity and
performance, and nutrition. Along with these measures, several other measures of
psychosocial functioning such as symptoms of depression, anxiety, and social activity
were assessed, most often for consideration as covariates in cognitive models. The
MSLS includes seven waves of examination with six participant cohorts defined by time
of entry into the study. A total of 2464 community-dwelling individuals have participated
in at least one examination of the MSLS (see Table 2.1).
The first four waves of the MSLS were conducted at the SUNY Health Science
Center in Syracuse, New York via collaboration between Merrill F. Elias, Principal
Investigator and David H. P. Streeten, Investigator and Professor of Medicine. In 1996,
the MSLS acquired its own laboratory space in Syracuse while collaborating with
medical staff at the SUNY Health Sciences Center. This study structure continued
through wave 6 and wave 7.

24

Table 2.1. Design of the MSLS
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E4
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E5

→

E6

E1
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E2

→
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E4
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E2

→

E3

→

E4

E1

→

E2

→

E3

E1

→

E2

C3
C4
C5
C6
C7

E1
W – Wave

C – Cohort

E – Examination

2.2 Sample and Design
Data were selected from the sixth [2001-2006] and seventh [2006-2011] waves
of the MSLS from non-institutionalized community-dwelling adults residing in Central
New York. Exclusions of MSLS participants were done on a study by study basis based
on medical, and social psychological, demographic information obtained during their
MSLS participation, including hospital and patient record (by permission). Exclusions
for the current study are described later. The University of Maine Institutional Review
Board approved this study (reference number: 2005-07-04) and informed consent was
obtained from all participants.
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For this study participants were excluded for the following: probable dementia (n
= 8), kidney dialysis (n = 5), and acute stroke (n = 28) at wave 6 or wave 7.
Additionally, 196 individuals were not invited back for participation in wave 7 due to
living outside of the Central New York area and the necessity that participants visit the
MSLS laboratory for assessment of pulse wave analysis and pulse wave velocity. Of
the 822 individuals eligible for study, 103 did not return for wave 7 for other reasons
(87.5% retention). Although we did not exclude those with mild cognitive impairment or
a history of depression treatment in order to obtain a wide range of continuously
distributed data for cognitive performance and depressive symptoms, we excluded
individuals with probable dementia (n = 8) as they were unable to complete much of the
MSLS cognitive test battery. Acute stroke (n = 28) and kidney dialysis (n = 5) are highly
related to both cognitive dysfunction and symptoms of depression and those with a
history of acute stroke were excluded due to their likely confounding effects (Elias et al.,
2009; Kauhanen et al., 1999; Sobreiro et al., 2014) on these outcomes.
Acute stroke is defined as suffering a focal neurological deficit of acute onset
lasting greater than 24-hours as determine by medical record review. A diagnosis of
probable dementia was based on MSLS cognitive battery performance, medical record
review, significant other interview, and consensus derived from expert committee review
(neuropsychologists, social psychologists, and a geriatric physician) based on National
Institute of Neurological Disorders and Communicative Diseases and
Stroke/Alzheimer’s Disease and Related Disorders (NINDS-ADRDA; Mckhann et al.,
2011) criteria.
2.3 Procedure
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For waves 6 and 7 paper and pencil questionnaires including demographic data,
job stress, sleep disturbance, Cornell Medical Index, general medical information, and
health habits (smoking, alcohol consumption, dietary data, etc.) were completed at
home within one week of arriving at the MSLS laboratory. Participants arrived at the
laboratory around 9:00 AM following a fasting period maintained since 12:00 AM unless
they were diagnosed with diabetes mellitus and physician approval was not obtained.
Once in the laboratory, participants provided additional medical interview information on
physical and mental health. Blood samples were then taken first when the participant
arrived followed by fifteen blood pressure measurements (5 each: sitting, standing, and
recumbent; GE DINAMAP 100DPC-120XEN; GE Healthcare), and pulse wave analysis
(wave 7).
Wave 6 and wave 7 assay collection methods for independent variables including
tHcy have been described in greater detail in (Elias et al., 2006). Plasma samples for
tHcy and B6 were stored at -40°C and shipped to Oxford and Cambridge, UK for
assessment. Samples for assays of cholesterol, creatinine, plasma B9/B12, and
glucose were stored on ice and sent to Centrex Clinical Laboratories, Syracuse, New
York. tHcy sample concentrations were analyzed using a fluorescence polarization
immunoassay (Axis-Shield, Dundee, UK) on an Abbott IMx auto-analyzer (Abbott
Laboratories, Chicago, IL, USA; Shipchandler & Moore, 1995). The average intraassay variation was within accepted norms reported by the Centers for Disease Control
(< 3.5%, CDC, 2015). Additional details regarding assay collection have been
described in Elias et al. (2006).
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In addition to the assays above, APOE genotype (collected at wave 6 or wave 7)
was defined as those with at least one APOE-E4 allele vs. other (4/4 genotype: 2.8%;
2/4, 3/4, and 4/4 combined genotypes: 22.8%). APOE genotyping was derived from
polymerase chain reaction and restriction enzyme digest with Hhal (Hixon & Vernier,
1990) at the Neuroscience Division, Medical School, University of Birmingham, UK.
Following assay collection, participants were provided with a light breakfast and then
given a physical examination and were interviewed regarding medical history,
medications, and current treatment. Figure 2.1 displays the different locations involved
in MSLS data collection as well as where specific assays were done.
Figure 2.1 MSLS Structure and Assessment Locations

Syracuse Lab

Oxford, UK

Cognition/Medical

Homocysteine

Centrex Syracuse
Panel + Vitamin B12
Cambridge, UK

Maine

Vitamin B6 + C-Reactive

Data/Admin

Following interview, participants completed the MSLS Neuropsychological
Battery of over twenty order-standardized tests from the Wechsler Memory ScaleRevised (WMS-R), the Wechsler Adult Intelligence Scale (WAIS and WAIS-III), MMSE,
and Boston Naming Test among several other assessments. All cognitive measures
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were completed in a uniform order to preserve the standardized subtest presentation
within each scale and participants were allowed breaks as needed between subtests.
Following the examination, participants were sent a summary of their medical and
cognitive examination with a request that they contact their personal care provider to
review the information.
Age and education were operationalized in number of years attained, sex (M/F)
and marital status (married or living with partner/ divorced, separated, single, or
widowed) were dichotomized as was ethnicity (Black/ Other) due to the low number of
non-Black minority participants (Black: 6.1%, Native American: 1.0%, Hispanic: 0.4%,
Asian: 0.1%) and to ensure consistency of coding with prior MSLS studies. Body Mass
Index (BMI) and obesity status (yes/no) were derived from objective measurement of
height and weight without heavy clothing. Self-reported number of close friendships,
social activity (Robbins et al., 1994), and recent life events (yes/no), and co-residency
(yes/no) were also evaluated for use as covariates.
The Zung Depression Inventory (ZDI; Zung, 1965) was used to measure
symptoms of depression at every wave of the MSLS. The ZDI is composed of 20 selfreported, Likert scale items ranging in frequency from 1 “a little of the time” to 4 “most of
the time” and summed to create a total raw score (see appendix A for item list). Raw
scores were then divided by 0.8, resulting in an index score range from 25 to 100
(Hunter & Murphy, 2011). At both wave 6 and wave 7, ZDI items showed good internal
consistency (α = .80). Index scores were used to represent the continuum of
depressive symptom severity rather than major depressive disorder incidence. For a
more thorough review on dimensional scale measurement and the associations
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between the ZDI and other depression scales see Crawford, Cayley, Lovibond, Wilson,
& Hartley (2011).
In order to aggregate the effect of an array of cardiovascular risk factors, the
Framingham CVD Risk Score, which has been shown to predict 10-year risk of
cardiovascular disease, was employed (D’Agostino et al., 2008). The Framingham CVD
Risk Score includes age and gender stratified weights based on assay results of total
cholesterol (TC), high density lipoprotein (HDL), smoking status (self-report), and
systolic blood pressure (measurement explained above) stratified by treatment status in
addition to diabetes mellitus diagnosis status (see item weights in Appendix B).
Estimated glomular filtration rate was determined from serum creatinine (two-point rate
test type utilizing Johnson and Johnson VITROS instrument; Ortho Clinical Diagnostics)
stratified by age, sex, and ethnicity (Levey, Bosch, & Lewis, 1999). Diabetes mellitus
was defined as those with a fasting glucose level of ≥ 126mg/dl (assay methods
described in Elias et al., 2006) or treatment for diabetes mellitus.
2.4 Cognitive Tests and Domains
Cognitive performance was originally assessed using the Wechsler Adult
Intelligence Scale (WAIS) and the Halstead-Reitan Neuropsychological Test Battery. In
1993, the Framingham Test Battery was included and specific tests were selected from
these and other measures were selected to be included in the Maine Syracuse
Longitudinal Study Test Battery at wave 6 in 2000. Subtests and scales included in the
battery were measured on continuous scales and used to create measures of several
cognitive domains/composites shown in Table 2.2.
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Principal components and factor analyses by Elias et al. (2006)., yielded four
broad cognitive domains within a Global composite (i.e., Visual-Spatial Memory and
Organization (VSOM), Verbal Episodic Memory, Scanning and Tracking, and Working
Memory) derived from the Z-transformed average of 17 different subtests. Additionally,
the WAIS Similarities subtest has been employed as a separate measure in the MSLS
because it loaded significantly across the above cognitive domains. In some later
studies an Executive Function composite was created (discussed below). For
descriptive purposes for this study and prior MSLS analyses, subtests were Ztransformed, summed with their respective composite subtests, and z-transformed
again to create standardized composite scores. Each composite score had a mean of
0.00 with a standard deviation of 1.00. Similarly, the Global composite was created by
taking the z-transformed average of all the individual subtests used in each composite,
consistent with established MSLS practice. For all models below, we analyzed
cognitive performance data for the Global composite, Visual-Spatial Memory and
Organization (VSOM), Verbal Episodic Memory, Scanning and Tracking, Working
Memory, as well as an expanded version of the Executive Function composite
employed in prior MSLS studies.
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Table 2.2 Descriptions of the Cognitive Tests Contributing to Each Composite Score
Composites/ Subtests
Verbal Episodic Memory
Logical Memory-Immediate Recall a
Logical Memory-Delayed Recall a
Hopkins Verbal Learning Test
Visual-Spatial Organization/Memory
Visual Reproductions-Immediate Recall a
Visual Reproductions-Delayed Recall a
Matrix Reasoning b
Block Design c
Object Assembly c
Hooper Visual Organization
Scanning and Tracking
Trail Making A d
Trail Making B d
Digit Symbol Substitution c
Symbol Search b
Working Memory
Digit Span Forward c
Digit Span Backward c
Letter-Number Sequence b
Controlled Oral Word Associations
a
Similarities
Executive Function
Trail Making B d
Controlled Oral Word Associations
Expanded Executive Function (current study)
Trail Making B – A
Controlled Oral Word Associations
Block Design c
Matrix Reasoning b

Cognitive Ability Measured
Immediate memory, verbal
Delayed memory, verbal
Verbal learning and memory
Immediate recall, visual memory, and visual-spatial problem solving
Delayed recall, visual memory and visual-spatial problem solving
Abstract reasoning and pattern recognition
Visual-spatial perception, organization and construction
Speed of visual-spatial organization
Visual-spatial organization; some demands on executive function
Visual scanning and tracking; concentration and attention
Trails A plus demands on executive function abilities
Psychomotor performance
Visual processing speed
Attention and concentration
Attention, concentration, and working memory
Information processing while holding information in memory
Verbal fluency and executive functioning
Abstract reasoning
Trails A plus demands on executive function abilities
Verbal fluency and executive functioning
Executive function/set shifting with Trails A scanning/tracking removed
Verbal fluency and executive functioning
Visual-spatial perception, organization and construction
Abstract reasoning and pattern recognition

aOrigin

Wechsler Memory Scale-Revised
Wechsler Adult Intelligence Scale III
cOrigin Wechsler Adult Intelligence Scale
dOrigin Halstead-Reitan Neuropsychological Test Battery
bOrigin
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2.4.1 Expanded Executive Function Measure
For this particular study, an expanded version of the original MSLS Executive
Function composite (i.e., Controlled Oral Word Associations and Trail Making Test B-A)
was developed. Two additional subtests (i.e,, Block Design and Matrix Reasoning)
were included in order to broaden the range of executive abilities assessed and to
increase reliability of the Executive Function construct. Subtests were included for
study based on their theoretical relevance to different aspects of Executive Function
(EF) and on their incremental improvement to scale reliability (wave 6 α = .77; wave 7 α
= .78). The Clock Drawing Test was considered for inclusion because of its widespread
use as a measure of Executive Function and planning (Juby, Tench, & Baker, 2002),
but it was ultimately dropped due to a lack of performance variability (i.e., ceiling effect)
for our sample.
The importance of the Executive Function measure for this study warrants a
detailed description of each of the component tests, Block Design, Matrix Reasoning,
Controlled Oral Word Association, and Trail-Making.
For the Block Design subtest (BD; Wechsler, 2003), participants were given
blocks which had red, white, and half red/half white sides. Participants were then asked
to use the blocks to match a visual pattern presented by the examiner as quickly as
possible. Time-to-completion and accuracy both factor into the scoring of BD
performance. Participants were presented with novel patterns which became
increasingly difficult until the participant consistently did not complete the pattern within
the allotted time, failed to correctly reproduce the pattern, or the participant completed
all patterns available, at which point the subtest was concluded. BD has been shown in
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other studies to be sensitive to variations in central executive function (updating),
prefrontal lobe damage, and age-related decline (Brown, Brockmole, Gow, & Deary,
2012; Friedman et al., 2006; Lezak, 2012).
For Matrix Reasoning (MR; Wechsler, 2003), participants were presented with an
incomplete pattern matrix and a set of five individual patterns from which to select to
complete the matrix pattern. Individual patterns are selected based on concepts such
as numbers and types of shapes, orientation, and color. Like BD, novel pattern
matrices were presented in standard order of increasing difficultly and participants
continued until all levels had been completed or when they consistently failed to choose
the correct pattern. Participant scores were determined by number of correctly
completed matrices. MR was selected as an alternative index of fluid reasoning
because unlike BD, participants were given as much time as needed to make their
selection, reducing the overall reliance on speeded processing.
For Controlled Oral Word Associations (COWA; Benton, 1967; Patterson, 2011),
participants were given one minute to verbally list as many words beginning with the
same letter (i.e., F) as possible. Two additional rounds were completed with different
letters (i.e., A, S). Participants were also asked not to repeat words, list proper nouns,
numbers, or repeat words with different suffixes (e.g., fence and fences). Participant
scores were determined by number of correctly listed words. COWA has been shown
to correlate moderately with other measures of executive function, including the
Wisconsin Card Sorting Task and Trail-Making Test – B and to be sensitive to
performance variability following antidepressant treatment for stroke patients and those
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with frontal lobe lesions (Duff, Schoenberg, Scott, & Adams, 2005; Levin, Eisenberg, &
Benton, 1991; Narushima, Paradiso, Moser, Jorge, & Robinson, 2007).
For The Trail-Making Test (Jurado & Rosselli, 2007; Reitan, 1958), participants
were given a sheet of paper which had circles distributed throughout. In Part A,
participants were asked to draw a trail to connect the circles in ascending order as
quickly as possible (circles were numbered 1-25). In Part B participants were given
another sheet of paper, only the circles included both numbers (1-13) and letters (A-L).
Participants were then asked to draw a trail to connect the circles in ascending order
alternating between numbers and letters (i.e., 1-A-2-B-3-C) as quickly as possible.
Time taken to complete the tasks was recorded in seconds, with less time representing
greater performance. The log-transformed difference in seconds between Part B and
Part A (TMT B-A) was calculated to minimize the effect of processing speed and to
better isolate demand on set shifting and response inhibition represented by Part B (Cui
et al., 2007; Jurado & Rosselli, 2007).
2.5 Statistical Methods
Statistical analyses initially consisted of selecting theoretically relevant
covariates, analyzing bivariate associations between covariates, the Executive Function
composite and symptoms of depression. Lastly, analysis of path models was
conducted with basic and extended sets of covariates.
2.5.1 Covariate Selection
Previous studies have identified several theoretically relevant covariates with
respect to Executive Function, tHcy, and symptoms of depression (see Appendix C).
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After identifying commonly occurring covariates in the literature, covariates were
eliminated initially based on a lack of association with any of the following: Executive
Function, tHcy, or symptoms of depression (p > .10).
A basic covariate set was employed in all analyses (age, sex, education,
ethnicity, and marital status) and other covariates were included based on their
contributions to model fit as represented by reductions in the χ2 statistic. However,
since the χ2 statistic is almost always significant (p < .05) with large sample sizes (n >
400; Kenny, 2015), other measures were employed which are not as prone to type-one
error (χ2/df, root mean squared error of approximation (RMSEA), and comparative fit
index (CFI). Although many of these variables did not have a considerable negative
impact on model fit statistics, diminishing returns on model fit were observed. Once
model fit indices were observed to be satisfactory, several covariates were excluded in
order to achieve model parsimony.
2.5.2 Cross-Lagged Panel Design
We utilized a structural equation modeling technique known as cross-lagged
panel design (CLPD, SPSS V.24 AMOS). In this study, wave 6 Executive Function
(EF1) and depressive symptoms (D1) and wave 7 Executive Function (EF2) and
depressive symptoms (D2) are the variables of interest. A simplified version of the
CLPD employed in this study is displayed in Figure 2.2 below. This CLPD produces 6
possible associations, 2 synchronous (cross-sectional; D1-EF1, D2- EF2), 2 autocorrelational (D1-D2, EF1-EF2) and 2 cross-lagged (EF1-D2, D1-EF2). This design
allows the 2 cross-lagged prospective associations between Executive Function and
depressive symptoms to be adjusted by wave 6 levels in order to examine change over
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time. Significant synchronous associations between EF1-D1 or EF2-D2 in the absence
of other associations would indicate that the relationships between Executive Function
and depressive symptoms may be epiphenomenal, but not indicative of predictive
change. Significant associations for only one of the cross-lagged paths imply a model
of unidirectional change over 5-years. Significant associations between the autocorrelations of D1-D2 and EF1-EF2, but not between the associations of the cross-lags
(EF1-D2 and EF1-D2) would indicate that Executive Function and depressive symptoms
are causally unassociated. Lastly, if the cross-lag of EF1-D2 > D1-EF2 then Executive
Function predicts depressive symptoms more than depressive symptoms predicts
Executive Function.
Figure 2.2 Simplified Model of Cross-Lagged Panel Design
_____________________________________________________________________

______________________________________________________________________
D1 and D2 are depressive symptoms at wave 6 and wave 7 respectively. EF1 and EF2
are Executive Function at wave 6 and wave 7 respectively. Straight lines represent
regression paths and curved lines represent paths of covariation.

After models were identified for Executive Function and ZDI as independent
predictors, we assessed the specificity of these relationships by substituting each
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cognitive domain (Global composite, Visual-Spatial Memory and Organization, Verbal
Episodic Memory, Scanning and Tracking, Working Memory) in the place of Executive
Function to determine the specificity of these associations. Cognitive domains were
measured as latent variables with subtest errors from wave 6 being covaried with
subtest errors from wave 7. ZDI was measured as a continuous observed variable from
the scoring scheme above. Pathways were assessed first in the presence of basic
covariates (age, sex, education, ethnicity, and marital status) and then in the presence
of an extended set of covariates.
2.5.3 Conditional Mediation Analyses
After the temporal precedence of Executive Function and depressive symptoms
was determined via CLPD analysis, the direct effects of wave 6 APOE-E4 genotype x
age x tHcy interactions on wave 7 depressive symptoms adjusted for wave 6 depressive
symptoms was examined. Simultaneously, we examined the indirect associations of
these three-way interactions and depressive symptoms through Executive Function. All
conditional mediation models were also adjusted for lower-order two-way interactions
and their respective main effects in addition to model covariates from the CLPD. Since
tHcy was of primary interest in these models, the direct and indirect (through Executive
Function/cognitive function) effects of tHcy on depressive symptoms were included in
the conditional mediation tables below. As was true for the CLPD analyses above, we
substituted each cognitive domain individually in the place of Executive Function in
these models to determine the specificity of these associations.
We estimated the parameters of our models from eligible participants with data at
wave 6 and wave 7 using maximum likelihood estimation for all analyses (CLPD EF
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Extended models, 21.1% any missing data; Conditional Mediation EF Extended models
9.0% any missing data). Standard errors and confidence intervals were estimated using
SPSS V.24 AMOS software bootstrapping techniques (5000 samples).
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3. RESULTS
3.1 Attrition, Demographic, and Health Variables
Table 3.1 shows demographic and health characteristics at wave 6 for
participants who completed both wave 6 and wave 7 (n = 719) and those who only
completed wave 6 because they were either unavailable (n = 103) or not invited back (n
= 196) for wave 7 analyses due to living outside of the Central New York area.
Compared with those that only completed wave 6 (n = 299), a lower proportion of those
that completed both waves were Black, were previously diagnosed with depression, and
were marginally less likely to be diabetic or taking psychotropic medications (p’s < .05).
Additionally, those that completed both waves had higher levels of functional
performance and marginally higher total cholesterol as well as lower levels of
depressive symptoms (ZDI), tHcy, and HDL (p’s < .10). Lastly, those that completed
both waves performed better across all domains of cognitive performance (p’s < .01).
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Table 3.1 Wave 6 Demographic and Health Characteristics
Participation Period
Wave 6 only
n = 299
62.31(14.77)

Variable
Age (years), M(SD)1
Sex (% female)

55.6

Education (years), M(SD)

14.52(2.84)

Both Waves
n = 719
62.09(11.93)

P-value

59.7
14.64(2.71)

Ethnicity (% Black)

10.7

6.1

Marital Status (% Cohabitating/Married)

59.1

64.7

*

Recent Life Events (%)

23.0

22.0

Social Activity, M(SD)1

20.81(5.94)

21.19(5.17)

76.0

77.5

Close Relationships, M(SD)

6.48(9.43)

6.39(6.63)

Functional Performance M(SD)1

1.17(1.26)

0.84(1.23)

***

44.01(9.38)

41.87(9.42)

**

11.94(43.06)

8.48(34.06)

Cohabitation (% living w/ others)

Zung Depression Inventory M(SD)
Cigarettes/week,

M(SD)1

Alcohol drinks/week, M(SD)
Body Mass Index, M(SD)

1.64(3.74)

1.47(2.54)

29.43(6.12)

29.18(5.84)

Homocysteine(μmol/L), M(SD)1

10.69(4.56)

9.66(3.14)

485.03(291.78)

475.20(233.94)

97.54 (105.15)

92.01(84.78)

M(SD)1

15.82(5.87)

15.24(5.30)

C-Reactive Protein, M(SD)

4.38(4.65)

3.99(4.55)

B12, nmol/L,

M(SD)1

B6, nmol/L M(SD)1
B9, ng/L

Mean Arterial Pressure, M(SD)
Total Cholesterol (Mg/DL), M(SD)
HDL, mg/DL, M(SD)
LDL, mg/DL, M(SD)

**

91.28(12.47)

90.50(12.74)

197.26(41.94)

202.82(39.44)

+

51.85(14.79)

53.88(15.41)

+

118.34(33.94)

121.18(33.07)

146.67(123.98)

142.95(108.11)

EPI-GFR, ml/min, M(SD)1

76.11(21.04)

77.86(16.43)

Framingham Score, M(SD)

13.45(6.04)

13.12(5.62)

Hypertension Meds (%)

55.0

51.0

Psychotropic Meds (%)

25.0

15.0

***

Diabetes (%)

16.0

11.0

+

Previous Depression Diagnosis (%)

20.0

12.0

*

Cardiovascular Disease (%)

15.4

12.8

Triglycerides, mg/DL, M(SD)

APOE-E4 (%)

23.3

28.0

Global Composite, M(SD)1

-0.14(1.04)

0.12(0.89)

***

Verbal Episodic Memory, M(SD)1

-0.13(1.07)

0.10(0.90)

**

-.12(1.21)

0.10(0.92)

**

-0.10(1.02)

0.10(0.93)

**

-.11(1.01)

0.09(0.95)

**

-0.14(1.03)

0.10(0.93)

**

Visual Spatial Organization and Memory,

M(SD)1

Scanning and Tracking, M(SD)1
Working Memory, M(SD)
M(SD)1

Expanded Executive Function Composite,
+ p < .10, *p < .05, ** p < .01 *** p < .001
1Equal variances not assumed
Categorical variables assessed with Fisher’s exact test
Cognitive Performance measured in z-score units
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3.2 Associations of Executive Function and other Domains
As expected, significant associations between the wave 6 Expanded Executive
Function composite and all other domains of cognitive performance were observed (p’s
< .001). Rather than emerging as an orthogonal construct, Executive Function was
highly associated with Global cognitive performance, Visual-Spatial Organization and
Memory (r’s > 0.80) and was moderately associated with Verbal Episodic Memory,
Working Memory, and Scanning and Tracking (0.20 < r’s < 0.80). Lastly, Executive
Function was moderately associated with the Similarities subtest which has been shown
in prior MSLS analyses to load significantly across all cognitive domains (Elias et al.,
2006). Table 3.2 displays zero-order correlations for all wave 6 domains of cognitive
performance.
Table 3.2 Zero-Order Correlations of Wave 6 Cognitive Domains
Wave 6
Variable
Executive
Function

Executive
Function
-

Global

Global

Working
Memory

Scanning &
Tracking

VSOM

0.887***

Verbal
Episodic
Memory
0.472***

0.645***

0.740***

0.847***

-

0.692***

0.711***

0.839***

0.886***

-

0.391***

0.437***

0.504***

-

0.500***

0.448***

-

0.690***

Verbal
Episodic
Memory
Working
Memory
Scanning
& Tracking
VSOM
Similarities

0.612***

0.663***

0.442***

0.387***

***p<.001, **p<.01, *p<.05 +p<.10
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0.452***

0.612***

3.3 Covariate Selection
The following variables measured at wave 6 and wave 7 were considered based
on the their common inclusion in the literature: age, sex, education, marital status,
ethnicity, diabetes mellitus status, CVD status, Framingham CVD Risk Score, social
activity, number of close relationships, smoking, cohabitation, measures of obesity,
alcohol consumption, high density lipoprotein (HDL), low density lipoprotein (LDL),
triglycerides, total cholesterol (TC), estimated glomular filtration rate/creatinine, vitamins
B6/B9/B12, hypertension status and continuously measured systolic/diastolic blood
pressure, physical function deficits (Dearborn, Robbins, & Elias, 2015), psychotropic
medications/anti-depressive medications, and previous depression diagnosis requiring
treatment (Appendix B).
Of the variables considered above, measures of hypertension, smoking,
estimated glomular filtration rate/creatinine, vitamins B9/B12, HDL, TC, triglycerides,
and smoking were dropped due to lack of associations with depressive symptoms (p’s >
.10). Measures of obesity, psychotropic/anti-depressive medications, and previous
depression diagnosis requiring treatment were dropped due to lack of associations with
Executive Function (p’s > .10). Alcohol consumption, cohabitation status, number of
close relationships, social activity, and LDL were dropped due to lack of associations
with tHcy (p’s > .10).
Table 3.3 shows model covariates surviving backward elimination. Physical
function deficits, diabetes mellitus status, vitamin B6, and CVD status were considered
for analysis based on their associations with Executive Function, depressive symptoms
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and tHcy, but were ultimately dropped because they did not contribute significantly to
model fit.
Table 3.3 Zero-Order Associations of Model Covariates Surviving Backward Elimination
Wave 6
Variable
Executive
Function

tHcy

Age

Sex

Education

Marital
Status

Ethnicity

Framingham

-0.151***

-0.394***

-0.020

0.386***

0.188***

-0.266***

-0.355***

Global

-0.194***

-0.491***

0.073+

0.390***

0.185***

-0.185***

-0.442***

Verbal
Episodic
Memory

-0.116**

-0.361***

0.124**

0.237***

0.057

-0.143***

-0.305***

Working
Memory

-0.106**

-0.217***

0.052

0.278***

0.096*

-0.214***

-0.256***

Scanning
&
Tracking

-0.234***

-0.523***

0.138***

0.307***

0.145***

-0.229***

-0.444***

VSOM

-0.154***

-0.462***

-0.017

0.340***

0.231***

-0.245***

-0.390***

ZDI

0.066+

0.090*

0.091*

-0.191***

-0.153***

0.073+

0.069+

0.200***

-0.261***

-0.052

0.058

0.077*

0.289***

tHcy

-

***p<.001, **p<.01, *p<.05 +p<.10
Wave 7 ZDI (tHcy r = 0.088, p = .023; Framingham r = 0.100, p = .010)

3.4 Cross-Sectional Associations of Cognitive Performance and Depressive
Symptoms
After adjustment for basic demographic covariates (Basic model: age, sex,
education, ethnicity, and marital status) and cardiovascular risk factors (Extended
model: tHcy and Framingham Risk Score), Executive Function was associated inversely
with depressive symptom severity (Table 3.4). Additionally, all other domains of
cognitive performance were associated inversely (p’s < .05) with depressive symptom
severity with the exception of Working Memory (p > .10). These wave 6 model
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covariates were employed in the prospective CLPD based on the methods described
above.
Table 3.4 Cross-Sectional Standardized (β) and Unstandardized (b) Regression
Coefficients of Wave 6 Cognitive Function Predicting Symptoms of Depression
Basic Model
Cognitive Outcome

β

b

Executive Function

-0.149***

-0.012***

Global

-0.157***

Verbal Episodic Memory

Extended Model
β

b

0.003

-0.146***

-0.012***

0.003

-0.005***

0.001

-0.156***

-0.005***

0.001

-0.077*

-0.007*

0.003

-0.078*

-0.007*

0.003

Working Memory

-0.022

-0.001

0.003

-0.022

-0.001

0.003

Scanning & Tracking

-0.140***

-0.011***

0.002

-0.137***

-0.011***

0.002

VSOM

-0.169***

-0.013***

0.002

-0.169***

-0.013***

0.002

SE

SE

***p <.001; * *p < 0.01; *p < 0.05
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + homocysteine, + Framingham Risk Score

3.5 5-year Cross-Lagged Associations of Cognitive Performance and Depressive
Symptoms
CLPD model fit statistics illustrated in Figure 2.2 are displayed in Table 3.5
below. Although model χ2 statistics were significant across all cognitive domain
models, RMSEA statistics range from excellent (Executive Function and Scanning and
Tracking RMSEA’s ≤ .05) to satisfactory (Global, Working Memory, Verbal Episodic
Memory, Visual Spatial Organization and Memory (RMSEA’s ≥ .06 < .09). These fit
statistics were similar across other measures of fit (CFI and χ2/df) with the exception of
Global cognitive performance models (CFI- Basic model = 0.811, CFI-Extended model
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= 0.816), which likely suffered from the comparatively larger number (n = 17) and
variability of subtests in the Global composite.
Table 3.5 Model Fit Statistics for 5-Year Cross-Lagged Panel Analyses
CFI
(Basic/Extended)
0.979 / 0.979

RMSEA
(Basic/Extended)
0.044 / 0.034

χ2(df)
(Basic/Extended)
139.142(58) /
161.840(70)

p-value
(all)
<0.001

Global

0.811 / 0.816

0.080 / 0.077

4539.375(814) /
4648.440(882)

<0.001

Working
Memory

0.945 / 0.954

0.065 / 0.060

235.583(58) /
248.316(70)

<0.001

Verbal
Episodic
Memory

0.955 / 0.962

0.086 / 0.076

213.055(34) /
216.637(42)

<0.001

Scanning and
Tracking

0.983 / 0.984

0.047 / 0.044

166.133(58) /
166.777(70)

<0.001

VSOM

0.937 / 0.940

0.069 / 0.066

Executive
Function

521.986(118) /
573.539(138)
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + homocysteine, + Framingham Risk Score
CFI = Confirmatory Fit Index
RMSEA = Root Mean Squared Error of Approximation

<0.001

3.5.1 Cognitive Function and Changes in Depressive Symptoms
After adjustment for wave 6 depressive symptom severity, demographic
covariates (Basic) and cardiovascular risk factors (Extended), lower wave 6 Executive
Function predicted increased depressive symptom severity at wave 7 (p < .05). This
pattern of results was similar across other wave 6 domains of cognitive functioning,
including Global cognitive performance, Scanning and Tracking, and Visual-Spatial
Reasoning and Memory (p’s < .05; VSOM Extended model p < .10). However, unlike
Executive Function, wave 6 Verbal Episodic Memory and Working Memory failed to
predict changes in depressive symptoms at wave 7. These results are displayed in
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Table 3.6 below. Additionally, a simplified version of the Executive Function CLPD
Extended Model is displayed in Figure 3.1 below. CLPD figures for the other remaining
cognitive domains are displayed in Appendix D.
Table 3.6 Cross-Lagged Standardized (β) and Unstandardized (b) Regression
Coefficients of Wave 6 Cognitive Function and Wave 7 Symptoms of Depression
Basic Model

Extended Model

Cognitive Outcome

β

b

SE

β

Executive Function

-0.108*

-1.348*

0.613

-0.099*

-1.241*

0.614

Global

-0.136**

-4.587**

1.658

-0.130**

-4.383**

1.653

Verbal Episodic Memory

-0.044

-0.474

0.365

-0.046

-0.493

0.364

Working Memory

-0.027

-0.427

0.605

-0.024

-0.319

0.605

Scanning & Tracking

-0.170***

-2.188***

0.599

-0.167***

-2.145***

0.598

VSOM

-0.093*

-1.189*

0.572

-0.086+

-1.107+

0.572

***p < .001; * *p < 0.01; *p < 0.05, p < .10
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + homocysteine, + Framingham Risk Score
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b

SE

Figure 3.1 Cross-Lagged Panel Analysis Executive Function Extended Model

Fit Indices
RMSE = 0.034
χ2(70) = 161.840, p < .001
χ2/df = 2.312
CFI = 0.979
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3.5.2 Depressive Symptoms and Changes in Cognitive Function
These CLPD analyses were conducted simultaneously with those presented
Table 3.6 with adjustment for wave 6 Executive Function to determine the 5-year
predictive value of wave 6 depressive symptoms on changes in Executive Function at
wave 7. These analyses were repeated in separate models with adjustment for all other
wave 6 domains of cognitive function. After adjustment for demographic covariates
(Basic) and cardiovascular risk factors (Extended), wave 6 depressive symptoms failed
to predict changes in Executive Function at wave 7 (p < .05). Similarly, wave 6
depressive symptoms failed to predict changes in wave 7 Global cognitive performance
and Visual-Spatial Organization and Memory, and Verbal Episodic Memory (p’s > .05).
However, unlike Executive Function, higher wave 6 depressive symptoms were
associated with decreased performance in wave 7 Working Memory and Scanning and
Tracking (p’s < .05). These results are presented in Table 3.7 below.
Table 3.7 Cross-lagged Standardized (β) and Unstandardized (b) Regression
Coefficients of Wave 6 Symptoms of Depression and Wave 7 Cognitive Function
Basic Model
Cognitive Outcome

β

b

SE

Extended Model
β

b

SE

Executive Function

-0.031

-.003

.002

-0.034

-0.003

0.002

Global

-0.020

-0.001

0.001

-0.022

-0.001

0.001

Verbal Episodic Memory

-0.049+

-0.005+

0.003

-0.047+

-0.005+

0.003

Working Memory

-0.084**

-0.005**

0.002

-0.086**

-0.006**

0.002

Scanning & Tracking

-0.040*

-0.003*

0.002

-0.042*

-0.004*

0.002

VSOM

-0.003

0.000

0.002

-0.005

0.000

0.002

* *p < 0.01; *p < 0.05; + p < .10
Basic model = wave 6 age, sex, education, ethnicity, marital status
Extended model = Basic model + homocysteine, + Framingham Risk Score
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3.5.3 Directional Findings of Cross-Lagged Panel Analyses
The results suggest significant unidirectional relationships with lower wave 6
Executive Function predicting increases in depressive symptoms at wave 7, but wave 6
depressive symptoms not predicting changes in wave 7 Executive Function. Similar
unidirectional results were found for Global cognitive performance, and Visual-Spatial
Organization and Memory. Different unidirectional patterns were found for Working
Memory, with higher wave 6 depressive symptoms predicting increases in wave 7
Working Memory. Lastly an inverse bidirectional trend was observed between
Scanning and Tracking and depressive symptoms, though wave 6 Scanning and
Tracking was a stronger predictor (Extended model: βstd = -0.167) of changes in wave
7 depressive symptoms compared with wave 6 depressive symptoms as a predictor of
changes in wave 7 Scanning and Tracking (Extended model: βstd = -0.042).
3.6 Conditional (Moderated by Age x APOE-E4) Effects of Homocysteine Mediated
Through Cognitive Function on Wave 7 Depressive Symptoms
Figure 3.2 and Figure 3.3 show simplified models of individual component path
coefficients for predicting wave 7 depressive symptoms from which direct, indirect, and
total effects can be calculated for the Basic and Extended model, respectively. Basic
wave 6 model covariates and wave 6 depressive symptoms were repeated from CLPD
analyses and Extended models included adjustments for wave 6 Framingham Risk
Score. Table 3.8 and Table 3.9 show the direct and indirect effects of tHcy,
Framingham Risk Score, and age x tHcy x APOE-E4 genotype interactions (adjusted for
all corresponding two-way interactions) in relation to wave 6 Executive Function, other
domains of cognitive performance, and wave 7 depressive symptoms for the Basic and
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Extended model, respectively. In all mediation analyses, age and tHcy were Ztransformed for clarity of interpretation.
Model χ2 statistics remained significant across all cognitive domain models and
RMSEA statistics again ranged from excellent (Executive Function and Scanning and
Tracking RMSEA’s ≤ .05) to adequate (Working Memory, Verbal Episodic Memory, and
Visual-Spatial Organization and Memory RMSEA’s ≤ .073) with the exception again of
Global performance models (Extended model RMSEA = .097).
3.6.1 Age x tHcy x APOE-E4 Effects
For both the Basic and Extended models, the direct paths of wave 6 tHcy x age
x APOE-E4 interaction were significantly associated with changes in wave 7 depressive
symptoms across all cognitive models (p’s < .01, Executive Function p < .05). However,
wave 6 tHcy x age x APOE-E4 interactions were unrelated to wave 6 performance
across all cognitive domains. Lastly the indirect paths from wave 6 age x tHcy x APOEE4 interaction to changes in wave 7 depressive symptoms as mediated by cognitive
performance were not significantly different from zero in all models (p’s > .05) with the
exception of Scanning and Tracking (p < .05).
3.6.2 tHcy Effects
The main effect of wave 6 tHcy was not associated with changes in wave 7
depressive symptoms or wave 6 cognitive performance across all models (p’s > .10).
Additionally, no mediation of the indirect path from wave 6 tHcy to wave 7 changes in
depressive symptoms was observed for any cognitive domains (p’s > .10).
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3.6.3 Framingham Risk Score Effects
Wave 6 Framingham Risk Score was positively associated with changes in wave
7 depressive symptoms in all cognitive models (p’s < .05; Global p < .10) with the
exception of Executive Function (p > .10). Additionally, wave 6 Framingham Risk Score
was inversely associated with wave 6 Executive Function (p < .01), Working Memory,
Visual Spatial Organization and Memory (p’s < .05), and marginally inversely associated
with wave 6 Global cognitive performance (p < .10). Additionally, no mediation of the
indirect path from wave 6 Framingham Risk Score to wave 7 changes in depressive
symptoms was observed for any cognitive domains (p’s > .10), with the exception of
Global cognitive performance (p < .05).
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Figure 3.2 Simplified Path Basic Model Showing Conditional Indirect Effects of tHcy
(Moderated by Age and APOE-E4) on Symptoms of Depression
______________________________________________________________________

A3

______________________________________________________________________
Lower-order two-way interactions (age x tHcy, age x APOE-E4 & tHcy x APOE-E4)
adjusted with wave 6 covariates
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Figure 3.3 Simplified Path Extended Model Showing Conditional Indirect Effects of tHcy
(Moderated by Age and APOE-E4) on Symptoms of Depression
______________________________________________________________________

A3

______________________________________________________________________
Lower-order two-way interactions (age x tHcy, age x APOE-E4 & tHcy x APOE-E4)
adjusted with wave 6 covariates
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Table 3.8 Component Path Coefficients (b) For the Direct and Indirect Effects of Age, tHcy, and APOE-E4 on Symptoms
of Depression Mediated through Cognitive Function (Basic Model).
Direct Effect Component Path
c’1

Cognitive Outcome
Executive Function
Global
Verbal Episodic
Memory
Working Memory

Scanning &
Tracking
VSOM

c’3

Indirect Effect Component
Path
a1
a3
b1

Indirect
Effect
ab1

ab3

b

0.056

-2.433**

0.007

0.053

-0.939

-0.006

-0.049

se

0.520

0.811

0.050

0.094

0.735

0.062

0.121

b

0.060

-2.313**

0.004

0.039

-3.755*

-0.041

-0.146

se

0.519

-0.812

0.029

0.013

1.808

0.054

0.139

b

0.070

-2.376**

0.041

0.066

-0.410

-0.017

-0.027

se

0.508

0.804

0.039

0.096

0.408

0.063

0.028

b

0.052

-2.514**

0.043

0.062

0.033

0.002

0.001

se

0.511

0.805

0.035

0.082

0.636

0.036

0.069

b

0.010

-2.199*

-0.024

0.167

-1.850**

0.044

-0.309*

se

0.515

0.809

0.033

0.079

0.622

0.067

0.184

b

0.063

-2.446**

0.016

0.028

-0.962

-0.015

-0.027

se

0.517

0.807

0.039

0.082

0.642

0.047

0.098

* *p < 0.01; *p < 0.05; +p < .10
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function
C’3 = Direct effect of tHcy x age x APOE-E4 interaction on wave 7 ZDI unmediated by cognitive function
A1 = Indirect component effect of tHcy on cognitive function
A3 = Indirect component effect of tHcy x age x APOE-E4 interaction on cognitive function
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function
Ab3 = Indirect effect of tHcy x age x APOE-E4 interaction on ZDI 7 mediated through cognitive function
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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Table 3.9 Component Path Coefficients (b) For the Direct and Indirect Effects of Age, tHcy, and APOE-E4 on Symptoms
of Depression Mediated through Cognitive Function (Extended Model).
Direct Effect Component Path
c’1

Cognitive Outcome
Executive Function
Global
Verbal Episodic
Memory
Working Memory

Scanning &
Tracking
VSOM

c’2

c’3

Indirect Effect
Component Path
a1
a2

Indirect Effect
a3

b1

ab1

ab2

ab3

b

0.015

0.144

-2.049**

0.007

-0.017**

0.055

-0.809

-0.012

0.014

-0.044

se

0.514

0.077

0.815

0.051

0.007

0.092

0.736

0.058

0.015

0.111

b

-0.008

0.143+

-2.343**

0.006

-0.004+

0.040

-3.518*

-0.021

0.014*

-0.139

se

0.513

0.076

0.817

0.013

0.002

0.029

1.793

0.053

0.010

0.133

b

-0.006

0.162*

-2.104**

0.039

0.003

0.066

-0.422

-0.017

-0.001

-0.028

se

0.501

0.076

0.808

0.039

0.008

0.095

0.412

0.028

0.005

0.064

b

-0.029

0.163*

-2.546**

0.050

-0.015*

0.064

0.159

0.008

-0.002

0.010

se

0.504

0.077

0.808

0.035

0.006

0.080

0.637

0.040

0.010

0.070

b

-0.061

0.151*

-2.223*

-0.022

-0.004

0.167*

-1.816**

-0.023

0.008

-0.304*

se

0.509

0.077

0.813

0.033

0.006

0.079

0.617

0.066

0.012

0.182

b

-0.007

0.146*

-2.471**

0.021

-0.012*

0.029

-0.863

-0.018

0.010

-0.025

se

0.511

0.076

0.811

0.040

0.006

0.081

0.641

0.046

0.010

0.081

* *p < 0.01; *p < 0.05; +p < .10
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + Framingham Risk Score
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function
C’2 = Direct effect of Framingham Risk Score on wave 7 ZDI unmediated by cognitive function
C’3 = Direct effect of tHcy x age x APOE-E4 interaction on wave 7 ZDI unmediated by cognitive function
A1 = Indirect component effect of tHcy on cognitive function
A2 = Indirect component effect of Framingham Risk Score on cognitive function
A3 = Indirect component effect of tHcy x age x APOE-E4 interaction on cognitive function
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function
Ab2 = Indirect effect of Framingham Risk Score on ZDI 7 mediated through cognitive function
Ab3 = Indirect effect of tHcy x age x APOE-E4 interaction on ZDI 7 mediated through cognitive function
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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3.7 Conditional Effects of Wave 6 Homocysteine (Moderated by Age) on Wave 7
Depressive Symptoms Mediated Through Cognitive Function
Due to significant three-way interactions between age, tHcy and APOE-E4
genotype, mediation path analyses were conducted separately for APOE-E4 carriers (n
= 189) and non-carriers (n = 483). Basic and Extended model covariates were repeated
from the above mediation analyses with adjustment for the main effects of age and tHcy
in determining the associations of tHcy x age interactions, cognitive function, and wave
7 depressive symptoms. Overall model fit statistics will be addressed, followed by
conditional mediation analyses by APOE-E4 genotype.
3.7.1 Model Fit Statistics
Prior model fit analyses were conducted with the combined statistical power of
APOE-E4 carriers and non-carriers combined (n = 719), resulting in significant χ2
statistics, indicating that the data were significantly different from what would be
expected. Although in APOE-E4 carrier (n = 189) Extended models χ2 statistics
remained significant, the Executive Function Extended model was not significantly
different from model expectations (p > 0.05). Additionally, RMSEA statistics indicated
excellent (Executive Function RMSEA = 0.028) to adequate fit (RMSEA’s ≤ 0.076) with
the exception of the Global Composite models (RMSEA = 0.112). Since there were
considerably more APOE-E4 non-carriers in our sample (n = 483), Extended model χ2
statistics remained significant across all domains. However, RMSEA’s were in the
excellent (Executive Function RMSEA = 0.049) to adequate range (RMSEA’s ≤ 0.076)
with the exception of the Global Composite and Working Memory models (RMSEA’s ≤
0.108).
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3.7.2 APOE-E4 Carriers – Age x tHcy Interaction Effects
Among APOE-E4 carriers in the Basic model (Table 3.10), significant
associations were observed for the direct path of wave 6 age x tHcy interactions to
changes in wave 7 depressive symptoms for the Visual-Spatial Organization and
Memory and Working Memory models (p’s < .05). However, in the Extended models
(Table 3.11), these direct associations fell to marginal significance for across all
cognitive models (p’s < .10) with the exception of Scanning and Tracking (p > .10). In
the Basic and Extended models, wave 6 age x tHcy interactions were not associated
with wave 6 performance for any cognitive domain, nor did any domain of cognitive
performance significantly mediate the indirect association of wave 6 age x tHcy
interactions and changes in wave 7 depressive symptoms (p’s > .10; Basic model
Executive Function p < .10).
3.7.3 APOE-E4 Carriers – tHcy Effects
For both the Basic and Extended models for APOE-E4 carriers (Table 3.10 and
Table 3.11), wave 6 tHcy was not associated with wave 6 performance for any cognitive
domain (p’s > .10). Additionally, wave 6 tHcy failed to predict changes in wave 7
depressive symptoms. Lastly, the indirect path from wave 6 tHcy and changes in wave
7 depressive symptoms was not significantly mediated by any cognitive domain (p’s
>.10).
3.7.4 APOE-E4 Carriers – Framingham Risk Score Effects
For APOE-E4 carriers, wave 6 Framingham Risk Score was inversely associated
with Global cognitive performance and Working Memory (p’s < .05; Table 3.11) and
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marginally inversely associated with Executive Function (p < .10). However, wave 6
Framingham Risk Score failed to predict changes in wave 7 depressive symptoms.
Lastly, the path from wave 6 Framingham Risk Score to changes in wave 7 depressive
symptoms was not significantly mediated by any domain of cognitive performance (p’s >
.10).
3.7.5 APOE-E4 Non-Carriers – Age x tHcy Interaction Effects
Among APOE-E4 non-carriers in the Extended models (Table 3.13), significant
positive associations between wave 6 tHcy x age and changes in wave 7 depressive
symptoms were observed across all cognitive models (p’s < .05; Global p < .10).
However, wave 6 tHcy x age interactions failed to significantly predict wave 6 cognitive
performance in all cognitive models with the exception of Scanning in Tracking (Table
3.12 Basic model p < .05) and Global cognitive performance (Basic model p < .10;
Extended model p < .05). Lastly, the path from wave 6 age x interactions to changes in
wave 7 depressive symptoms was not significantly mediated by any domain of cognitive
performance (p’s > .10) with the exceptions of Scanning and Tracking (Basic and
Extended model p’s < .05) and Global cognitive performance (Basic and Extended
model p’s < .10).
3.7.6 APOE-E4 Non-Carriers – tHcy Effects
For both the Basic and Extended models for APOE-E4 non-carriers (Table 3.12
and Table 3.13), wave 6 tHcy was not associated with wave 6 performance for any
cognitive domain (p’s > .10) with the exception of Scanning and Tracking (Extended
model p < .05). Additionally, wave 6 tHcy failed to predict changes in wave 7
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depressive symptoms across all cognitive models (p’s > .10). Lastly, the path from
wave 6 tHcy and changes in wave 7 depressive symptoms was not significantly
mediated by any cognitive domain (p’s >.10).
3.7.7 APOE-E4 Non-Carriers – Framingham Risk Score Effects
For APOE-E4 non-carriers, wave 6 Framingham Risk Score was not associated
with performance in any cognitive domain (p’s > .10) with the exception of Executive
Function (Table 3.13; p < .10). Additionally, wave 6 Framingham Risk Score failed to
predict changes in wave 7 depressive symptoms (p’s > .10). Lastly, the path from wave
6 Framingham Risk Score to changes in wave 7 depressive symptoms was not
significantly mediated by any domain of cognitive performance (p’s > .10).
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Table 3.10 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of
Depression Mediated through Cognitive Function (Basic Model) for APOE-E4 Carriers
Direct Effect Component Path
c’1

Cognitive Outcome
Executive Function
Global
Verbal Episodic
Memory
Working Memory

Scanning &
Tracking
VSOM

c’3

Indirect Effect Component
Path
a1
a3
b1

Indirect
Effect
ab1

ab3

b

0.450

-1.110

-0.068

0.025

-1.883

0.128

-0.046+

se

0.662

0.643

0.075

0.084

1.377

0.208

0.203

b

0.550

-1.106+

0.010

0.012

-3.860

0.040

-0.046

se

0.648

0.622

0.027

0.028

3.501

0.138

0.141

b

0.566

-1.126+

-0.022

0.068

-0.466

0.010

-0.032

se

0.654

0.616

0.087

0.082

0.763

0.075

0.094

b

0.592

-1.171*

-0.083

0.050

0.250

-0.021

0.013

se

0.651

0.623

0.076

0.070

1.139

0.133

0.100

b

0.661

-0.964+

0.029

0.072

-2.664*

-0.078

-0.193

se

0.637

0.616

0.065

0.067

1.264

0.196

0.215

b

0.560

-1.160*

-0.027

-0.007

-1.100

0.029

0.007

se

0.652

0.623

0.067

0.075

1.244

0.121

0.123

* *p < 0.01; *p < 0.05, +p < .10
N = 189
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function
A1 = Indirect component effect of tHcy on cognitive function
A3 = Indirect component effect of tHcy x age interaction on cognitive function
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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Table 3.11 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of
Depression Mediated through Cognitive Function (Extended Model) for APOE-E4 Carriers
Direct Effect Component Path
c’1

Cognitive Outcome
Executive Function
Global
Verbal Episodic
Memory
Working Memory

Scanning &
Tracking
VSOM

Indirect Effect Component Path

Indirect Effect

c’2

c’3

a1

a2

a3

b1

ab1

ab2

ab3

b

0.351

0.135

-1.067+

-0.048

-0.024+

0.016

-1.715

0.083

0.041

-0.027

se

0.656

0.147

0.651

0.072

0.014

0.082

1.414

0.185

0.044

0.189

b

0.626

0.145

-1.061+

-0.004

-0.008*

0.009

-3.401

0.013

0.028

-0.031

se

0.644

0.143

0.629

0.026

0.005

0.027

3.486

0.122

0.030

0.129

b

0.420

0.178

-1.061+

-0.028

0.007

0.071

-0.485

0.014

-0.003

-0.034

se

0.623

0.140

0.623

0.085

0.018

0.087

0.766

0.078

0.018

0.095

b

0.455

0.192

-1.117+

-0.057

-0.030*

0.039

0.522

-0.030

-0.016

0.020

se

0.646

0.144

0.628

0.071

0.012

0.067

1.174

0.112

0.039

0.096

b

0.535

0.151

-0.916

0.037

-0.009

0.069

-2.570*

-0.096

0.024

-0.178

se

0.637

0.143

0.624

0.065

0.010

0.067

1.275

0.191

0.031

0.210

b

0.434

0.156

-1.104+

-0.012

-0.017

-0.013

-0.958

0.012

0.017

0.012

se

0.646

0.143

0.631

0.065

0.013

0.074

1.258

0.110

0.029

0.117

* *p < 0.01; *p < 0.05, +p < .10
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + Framingham Risk Score
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function
C’2 = Direct effect of Framingham Risk Score on wave 7 ZDI unmediated by cognitive function
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function
A1 = Indirect component effect of tHcy on cognitive function
A2 = Indirect component effect of Framingham Risk Score on cognitive function
A3 = Indirect component effect of tHcy x age interaction on cognitive function
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function
Ab2 = Indirect effect of Framingham Risk Score on ZDI 7 mediated through cognitive function
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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Table 3.12 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of
Depression Mediated through Cognitive Function (Basic Model) for APOE-E4 Non-Carriers
Direct Effect Component Path
c’1

Cognitive Outcome
Executive Function
Global
Verbal Episodic
Memory
Working Memory

Scanning &
Tracking
VSOM

c’3

Indirect Effect Component
Path
a1
a3
b1

Indirect
Effect
ab1

ab3

b

0.094

1.034*

0.009

-0.027

-0.645

-0.006

0.018

se

0.528

0.518

0.049

0.050

0.892

0.057

0.065

b

0.092

0.946+

0.003

-0.022+

-3.995+

-0.011

0.087+

se

0.530

0.517

0.012

0.015

2.483

0.054

0.083

b

0.108

1.055*

0.049

-0.029

-0.342

-0.017

0.010

se

-0.519

0.517

0.038

0.049

0.485

0.033

0.034

b

0.098

1.064*

0.041

-0.006

-0.154

-0.006

0.001

se

0.524

0.518

0.033

0.043

0.814

0.042

0.036

b

0.039

0.955+

-0.033

-0.074*

-1.587*

0.053

0.118*

se

0.523

0.511

0.033

0.033

0.777

0.066

0.082

b

0.099

1.004+

0.015

-0.031

-1.027

-0.016

0.032

se

0.530

0.517

0.036

0.047

0.791

0.050

0.070

* *p < 0.01; *p < 0.05, p < .10
N = 483
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function
A1 = Indirect component effect of tHcy on cognitive function
A3 = Indirect component effect of tHcy x age interaction on cognitive function
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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Table 3.13 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of
Depression Mediated through Cognitive Function (Extended Model) for APOE-E4 Non-Carriers
Direct Effect Component Path
c’1

Cognitive Outcome
Executive Function
Global
Verbal Episodic
Memory
Working Memory

Scanning &
Tracking
VSOM

Indirect Effect Component Path

Indirect Effect

c’2

c’3

a1

a2

a3

b1

ab1

ab2

ab3

b

0.027

0.132

1.100*

0.016

-0.014+

-0.034

-0.539

-0.009

0.008

0.018

se

0.526

0.091

0.517

0.050

0.008

0.050

0.889

0.056

0.016

0.064

b

0.026

0.130

1.011+

0.004

-0.002

-0.023*

-3.827+

-0.015

0.009

0.088+

se

0.527

0.091

0.517

0.012

0.002

0.015

2.460

0.054

0.011

0.082

b

0.037

0.140

1.119*

0.048

0.000

0.029

-0.340

-0.016

0.000

0.010

se

0.517

0.091

0.517

0.039

0.009

0.049

0.489

0.033

0.006

0.034

b

0.025

0.140

1.131*

0.046

-0.010

-0.011

-0.068

-0.003

0.001

0.001

se

0.521

0.092

0.518

0.034

0.007

0.044

0.816

0.046

0.010

0.037

b

-0.029

0.136

1.019*

-0.032*

-0.002

-0.075

-1.569*

0.051

-0.002

-0.073*

se

0.522

0.091

0.512

0.034

0.007

0.034

0.772

0.066

0.013

0.083

b

0.033

0.130

1.070*

0.020

-0.010

-0.036

-0.944

-0.019

0.009

0.034

se

0.527

0.090

0.517

0.037

0.007

0.047

0.787

0.050

0.011

0.050

* *p < 0.01; *p < 0.05, + p < .10
N = 483
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + Framingham Risk Score
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function
C’2 = Direct effect of Framingham Risk Score on wave 7 ZDI unmediated by cognitive function
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function
A1 = Indirect component effect of tHcy on cognitive function
A2 = Indirect component effect of Framingham Risk Score on cognitive function
A3 = Indirect component effect of tHcy x age interaction on cognitive function
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function
Ab2 = Indirect effect of Framingham Risk Score on ZDI 7 mediated through cognitive function
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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3.8 Johnson-Neyman Moderation Analysis
In order to explore the continuous nature of age’s moderation effect on the
association between wave 6 tHcy and changes in wave 7 depressive symptoms, we
employed the Johnson-Neyman technique (P. O. Johnson & Fay, 1950). Unlike
traditional “pick a point” moderation analysis, which requires the investigator to analyze
age categories according to arbitrary cut-off points to observe differential effects of the
predictor variable (tHcy), the Johnson-Neyman technique uses the entirety of available
data to estimate the age regions where the effects of wave 6 tHcy on changes in wave 7
depressive symptoms are statistically significant. In addition to specificity, this
technique has the benefit of preserving statistical power compared with splitting the data
according to arbitrary cut-off points. Due to the significant associations of the three-way
interactions of wave 6 age x tHcy x APOE-E4 and changes in wave 7 depressive
symptoms, the interaction of age x tHcy was analyzed separately for APOE-E4 carriers
and non-carriers. Although age x tHcy interactions did not reach the level of
significance in the APOE-E4-carrier Extended models, the marginal trend for age x tHcy
interactions (p < 0.10) warranted further exploration as did the apparent inversion of the
wave 6 age x tHcy interaction effect on changes in wave 7 depressive symptoms for
APOE-E4 non-carriers.
Johnson-Neyman moderation analyses are shown in Table 3.14 for APOE-E4
non-carriers by 10th, 25th, 50th, 75, and 90th age percentile ranks. In the Basic model,
the effect of wave 6 tHcy on changes in wave 7 depressive symptoms was significant (p
< .05) for individuals ≥ 75.39 years of age. These results were similar for the Extended
model with significant effects for individuals ≥ 74.33 years of age (p < .05), indicating
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increases in symptoms of depression with higher levels of tHcy among older adults.
Figure 3.4 shows the simple slope of wave 6 tHcy on changes in wave 7 depressive
symptoms by age for APOE non-carriers for the extended model.
Table 3.14 Effects (b) of Wave 6 tHcy by Age Category on Wave 7 Symptoms of
Depression for APOE-E4 Non-Carriers
Basic Model
Age

b

Extended Model
SE

b

SE

47

-1.245

0.865

-1.431

0.869

54

-0.636

0.616

-0.767

0.619

62

0.060

0.427

-0.008

0.429

71

0.843+

0.497

0.845+

0.498

78

1.452*

0.712

1.414*

0.678

* *p < 0.01; *p < 0.05, + p < .10
N = 483
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + Framingham Risk Score

Johnson-Neyman moderation analyses are shown in Table 3.15 for APOE-E4
carriers by 10th, 25th, 50th, 75, and 90th age percentile ranks as well. Age category cut
offs differed slightly, but sensitivity analysis did not indicate any significant differences of
mean age between the groups (MD = 1.650. SE = 1.018, p = .11) nor considerable
differences in age variance (p > 0.25). As expected, no significant associations were
observed for APOE-E4 carriers. However, there was a marginal association (p < .10) of
higher wave 6 tHcy and increases in wave 7 depressive symptoms for adults ≤ 51 years
of age in the Basic model and ≤ 45 years of age in the Extended model. Figure 3.5
shows the simple slope of wave 6 tHcy on changes in wave 7 depressive symptoms by
age for APOE carriers for the extended model.
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Table 3.15 Effects (b) of Wave 6 tHcy by Age Category on Wave 7 Symptoms of
Depression for APOE-E4 Carriers
Basic Model
Age

b

Extended Model
SE

b

SE

45

2.192+

1.124

1.912+

1.140

51

1.645+

0.864

1.396

0.882

61

0.733

0.676

0.536

0.690

69

0.004

0.859

-0.153

0.865

77

-0.726

1.215

-0.841

1.215

* *p < 0.01; *p < 0.05, + p < .10
N = 189
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI
Extended model = Basic model + Framingham Risk Score

3.9 Sensitivity Analysis: Conditional Effects of Wave 6 Framingham Risk Score
(Moderated by Age and APOE-E4) on Wave 7 Depressive Symptoms
Due to significant conditional effects of wave 6 tHcy on changes in wave 7
depressive symptoms (moderated by age and APOE-E4), we explored whether these
same three-way interaction patterns held for Framingham Risk score (age x APOE-E4 x
Framingham Risk Score). In a Basic model, we adjusted for wave 6 age, sex,
education, ethnicity, and marital status as well as lower-order two-way interactions and
main effects of APOE-E4 and Framingham Risk Score. In the Basic model, we did not
observe a significant three-way interaction effect of age x APOE x Framingham Risk
Score on changes in wave 7 depressive symptoms (b = -0.778, SE = 0.540, p = 0.16).
These results remained similar with the addition of tHcy as a model covariate (b = 0.769, SE = 0.540, p = 0.16).

67

Figure 3.4 tHcy Effect Slope (b) and 95% Confidence Intervals by Age for APOE-E4
Non-Carriers
_____________________________________________________________________

tHcy Slope (z-score)
84.9% of Sample

16.1% of Sample

Age
______________________________________________________________________
Figure obtained using Johnson-Neyman technique.
Solid vertical line represents area of significance (p < 0.05). Significant positive effects of wave 6 tHcy on
wave 7 ZDI were found for individuals ≥ 74.33 years of age.
Adjusted for wave 6 age, sex, education, marital status, ZDI and Framingham Score
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Figure 3.5 tHcy Effect Slope (b) and 95% Confidence Intervals by Age for APOE-E4
Carriers
______________________________________________________________________

tHcy Slope (z-score)
Age
____________________________________________________________________________________
Figure obtained using Johnson-Neyman technique.
No significant moderation of slope.
Adjusted for wave 6 age, sex, education, marital status, ZDI and Framingham Scor
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3.10 Summary of Results
In wave 6 cross-sectional analyses, higher Executive Function and other
cognitive functions, with the exception of Working Memory, were associated with lower
levels of depressive symptoms adjusted for age, sex, education, ethnicity, tHcy, and
Framingham Risk Score. In CLPD analyses bidirectional associations between
symptoms of depression and Executive Function were not observed. Rather,
unidirectional associations were observed with higher wave 6 Executive Function
predicting decreases in symptoms of depression at wave 7. These associations were
also observed for wave 6 Global cognitive function and Visual-Spatial Organization and
Memory function in relation to wave 7 depressive symptoms. Higher wave 6 depressive
symptoms were not undirectionally associated with lowered wave 7 Executive Function
and a similar pattern of non-significant results was observed for all other domains of
cognitive function with the exception of Working Memory. Finally, unlike Executive
Function, Scanning and Tracking was bidirectionally associated with depressive
symptoms, however the inverse association of wave 6 Scanning and Tracking and wave
7 depressive symptoms was stronger than what was observed of wave 6 depressive
symptoms and wave 7 Scanning and Tracking.
For conditional mediation models the direct path of age x tHcy x APOE
interactions were significantly associated with changes in depressive symptoms at wave
7, however, there was no direct main effect of tHcy or indirect effect through Executive
Function or other domains of cognitive functioning. However, higher Framingham Risk
scores at wave 6 were directly associated with increases in wave 7 depressive
symptoms and were indirectly associated with depressive symptoms through Executive
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Function. Similar to Executive Function, significant indirect paths through Working
Memory and Visual-Spatial Organization and Memory were also observed.
Among APOE-E4 carriers, Framingham Risk score was not indirectly associated
with changes in depressive symptoms through Executive Function. However, this path
was significantly different from zero through Working Memory and Global Function.
Additionally APOE-E4 carriers with higher tHcy experienced marginal increases in
depressive symptoms at less than 51 years of age. For APOE-E4 non-carriers, higher
tHcy was also associated with increases in depressive symptoms, but these
associations were delayed until after 74 years of age.
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4. DISCUSSION
The purpose of this study was to explore the associations of Executive Function,
homocysteine, and depressive symptoms. In the first phase of the study, we explored
the cross-sectional associations of cognitive function and symptoms of depression. In
the following phase, we explored the bidirectional associations of Executive Function
and other domains of cognitive function and depressive symptoms. Based on the
results of this phase, we explored the conditional mediation effect of homocysteine and
the Framingham Risk Score (modified by age and APOE-E4 status) through Executive
Function on changes in depressive symptoms. At each phase, we explored the
specificity of these relationships with Executive Function as compared with a full range
of cognitive domains.
4.1 Cross-Sectional Association of Symptoms of Depression and Cognitive
Performance
Our cross-sectional results are consistent with those observed by Hammar &
Ardal (2009). Several domains of cognitive performance were negatively associated
with symptoms of depression both with and without adjustment for age, sex, education,
ethnicity, and CVD-RF’s (Framingham Risk Score and tHcy). This is also consistent
with cross-sectional studies which have found that individuals with vascular disease and
high CVD risk profiles tend to be at a higher risk for depressive symptoms and lower
cognitive performance (Crichton et al., 2014; Hajjar et al., 2009; Kauhanen et al.,
1999). However, few studies have examined the longitudinal associations of these
variables, which has limited our ability to infer directionality, and no studies to our
knowledge have examined the potential mediating role of cognitive function on changes
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in symptoms as moderated by age and APOe-E4 genotype. Because the vascular
depression hypothesis asserts that aging–related processes may underlie the
associations of cognitive function and symptoms of depression, it is epidemiologically
relevant to analyze these relationships over time in the context of an ever-aging U.S.
population (Ortman et al., 2014). Moreover, the longitudinal design of this study allowed
us to adjust for baseline cognitive performance and depressive symptoms, which adds
to the predictive value of aging models. In the following sections, we discuss the
longitudinal findings of this study as they relate to the broader base of literature,
strengths and limitations, future directions, and their clinical implications.
4.2 Directional Associations of Symptoms of Depression and Cognitive
Performance
Inverse unidirectional associations were observed, with several domains of
cognitive performance predicting changes in symptoms of depression over the 5-year
interim, however, the reverse association was largely not found. These results are
consistent with the observations of Perrino et al. (2008) who assessed general cognitive
function using the Color Trails Test, Part 2 (D’Elia, Satz, Uchiyama, & White, 1996), the
California Verbal Learning Test (Delis, Kramer, Kaplan, & Ober, 2000), and the Fuld
Object Memory Evaluation (Fuld, 1977). However, these results differ from those
obtained by Cui, Lyness, Tu, King, and Caine (2007), who found that depression
diagnosis unidrectionally predicted Trails-B and Trails B-A times, but not the reverse.
There are a few possible reasons why our results differ from those obtained by
Cui, Lyness, Tu, King, and Caine (2007). Firstly, unlike the current study and Perrino et
al. (2008), Cui et al. did not adjust for baseline cognitive functioning, which may have
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otherwise diminished the predictive power of depression diagnosis. Second, Cui et al.
defined depression diagnosis using multinomial coding (3 levels) rather than measuring
symptoms continuously as was the case in the current study and in Perrino et al. This
may have in turn reduced the predictive power of cognitive function in their study.
Lastly, although both the current study and Cui et al. adjusted for CVD-RF’s and used
Executive Function measures as predictors, the current study and Perrino et al.
measured Executive Function (and cognitive function more broadly) using multiple
subtests to estimate performance, likely increasing the reliability of the measure. This is
a particularly important point as individual measures of Executive Function have been
shown to have poorer reliability compared with other measures of cognitive function
(i.e., processing speed; Miyake et al., 2000), possibly because performance on tasks
used to index Executive Function may depend on developing an optimal strategy which
might occur in a stepwise rather than a continuous fashion, leading to an immediate
increase in performance. Conversely, should one repeat the same strategy,
performance may increase only slightly, stay the same or may become inappropriate,
leading to an immediate drop in performance (Rabbit, Lowe, & Shilling, 2001). Using
multiple measures to estimate Executive Function may better capture the diverse nature
of the construct without considering all measurement variance as random error.
4.3 Homocysteine and Depressive Symptoms
Zero-order correlations showed inconsistent inverse associations between wave
6 tHcy and wave 6 and wave 7 depressive symptoms and the main effects of tHcy on
depressive symptoms were largely absent in the presence of demographic and CVD-RF
covariates for a pooled-age sample of community-dwelling adults. These results are
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contrary to those observed in a meta-analysis by Almeida et al. (2008). However,
almost all of the studies included in the meta-analysis observed differences in tHcy level
by MDD/clinically significant symptom status rather than depressive symptoms
measured continuously. While measuring these variables continuously increases
statistical power, it is possible that the associations between tHcy and symptoms of
depression are more subtle with a healthy community-dwelling, sample due to a
restriction of symptom severity.
4.4 Homocysteine Moderated by Age and APOE-E4
Although the main effects of tHcy on changes in depressive symptoms were
largely absent after adjusting for a range of demographic and CVD-RF’s in an agepooled sample (adjusted for three and two-way interactions), as hypothesized, the
effects of tHcy on 5-year changes in symptoms were dependent upon age and APOEE4 status. It is possible that the reason Almeida et al. (2008) observed mainly positive
associations between high tHcy and depression was that their analyses were almost
entirely limited to older adults. Contrary to our expectations however, positive
associations between the age x tHcy interaction and changes in depressive symptoms
were observed for APOE-E4 non-carriers rather than APOE-E4 carriers. It is important
to note that research thus far on APOE-E4 status and depressive symptoms is limited
and has been inconsistent (Niti et al., 2009; Skoog et al., 2015). This is the first study to
our knowledge to explore the moderating effect of APOE-E4 in concert with tHcy for
changes in depressive symptoms.
Although these findings seem contradictory, it is also important to note that
associations between the interaction of age x tHcy by APOE-E4 genotype and wave 7
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ZDI reflect residual change scores from wave 6 to wave 7 (adjusted for wave 6 ZDI)
rather than absolute levels of depressive symptoms. This is evidenced by high levels of
tHcy never emerging as a protective factor for depressive symptoms for APOE-E4
carriers, as associations of high tHcy and advancing age never approached significance
for symptom reduction. However, we did observe marginally higher risk for symptom
increases among younger to middle-aged adult APOE-E4 carriers. Second, we
observed among APOE-E4 non-carriers that the risks associated with high tHcy for
increases in depressive symptoms were not significant until after 74 years of age.
Rather than APOE-E4 non-carrier status presenting as a symptom risk factor as a
function of high tHcy compared with carrier status, the direction and strength of these
associations may represent a compression or delay of the negative symptom effects of
high tHcy for APOE-E4 non-carriers compared with carriers.
4.5 Framingham Risk Score in Relation to Depressive Symptoms and Cognitive
Performance
Although associations for Framingham Risk Score were not hypothesized a
priori, it is worth noting that higher Framingham Risk Score was associated with
increases in depressive symptoms and lower levels of cognitive performance for the
combined sample (n = 719) across several cognitive models. Additionally, Framingham
Risk Score was a more consistent predictor of cognitive performance than either the
interaction of tHcy x age x APOE-E4 or the main effect of tHcy. One possible reason for
these findings is that compared with tHcy, Framingham Risk Score represents a more
complete CVD-RF profile. However, there is also evidence that inclusion of tHcy level
in Framingham Risk Scores may increase predictive value for CVD outcomes
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(Veeranna et al., 2011). Additionally, the predictive value of tHcy for cognitive deficit
and CVD may depend on advanced age (Elias et al., 2005; Rodondi et al., 2012).
Though Framingham Risk Score is a well-recognized measure for assessing CVD risk
and has been consistently associated with higher depressive symptoms and lower
cognitive functioning in cross-sectional studies (Hajjar et al., 2009; Kaffashian et al.,
2011; Kivimäki et al., 2012), other analyses have failed to find associations between
Framingham/Stroke Risk Scores and subsequent increases in depressive symptoms
(Cui et al., 2007; Kivimäki et al., 2012). To our knowledge, this is the first study to
observe these associations across such a wide age range of adults.
4.6 Specificity of Executive Function Findings
The focus of this study was to extend the vascular depression hypothesis
literature, which primarily implicates Executive Function decline as a cognitive risk factor
for increases in depressive symptoms and MDD relapse. However, our results indicate
that the associations between cognitive function, CVD-RF’s, and symptoms of
depression are more general rather than specific to Executive Function.
First, the CLPD findings of this study appeared to be similar across several
domains of cognitive function, including Global cognitive performance, Visual-Spatial
Organization and Memory, and Scanning and Tracking, indicating that the associations
of cognitive function and depressive symptoms are more general rather than specific,
consistent with the meta-analysis by Hammar & Ardal (2009). It is important to note that
this may be in large part due to the composition of our Executive Function variable,
which includes subtests from the Visual-Spatial Organization and Memory (i.e., Matrix
Reasoning and Block Design) and Scanning and Tracking (i.e., Trails A and Trails B)
77

domains, which are all also contained within the Global composite. However, the
Working Memory domain also contained a subtest within our measure of Executive
Function (i.e., Controlled Oral Word Association) and the reverse unidirectional finding
(ZDI → WM) was observed. This indicates that shared subtest makeup does not alone
explain these generalized findings.
Our expanded measure of Executive Function was built upon established MSLS
operationalizations of the construct which emphasized planning and set shifting (Elias et
al., 2006; Robbins, Elias, Budge, Brennan, & Elias, 2005). However, several subtests
across other MSLS composites which were not included in our expanded measure also
require fluid ability and related demands upon aspects of Executive Function such as
attention, Working Memory, and set shifting (Table 2.2), making the true distinction of
our Executive Function composite and other domains unclear. Additionally,
independent of overlaps with fluid ability composites in the MSLS, measures such as
Matrix Reasoning and Block design have been represented both in the WAIS and the
Cattell Culture Fair Tests (Matrix Reasoning) as surrogates of fluid ability (Cattell, 1949;
Wechsler, 1981).
Although Executive Function and other several other domains of cognitive
function largely predicted unidirectional changes in depressive symptoms, in conditional
mediation analyses, Executive Function and other cognitive functions broadly were
inconsistent/weak mediators of the paths from wave 6 CVD-RF’s (tHcy, tHcy x age x
APOE-E4 interaction, Framingham Risk Score) and changes in depressive symptoms.
Although there were some exceptions to the pattern of broadly null mediation results, it
is important to note the inherently increased risk for type 1 error in multiple model
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mediation testing. As such, the pattern of null mediation results reflects a generalized
finding similar to the CLPD despite being contrary to our mediation hypotheses.
Perhaps the most obvious reason for the generalized pattern of our cognitive
models is that Executive Function is a heterogeneous construct composed of several
moderately associated components (e.g., Working Memory, response inhibition, mental
flexibility; Alvarez & Emory, 2006; Diamond, 2014) which fall within the conceptual
umbrella of fluid ability. Previous MSLS principal component analyses have established
that a single factor within the MSLS battery accounts for about 62% of performance
variance with the next most explanatory factor accounting for just 14% of measurement
variance (Elias et al., 2006). Furthermore, the expanded Executive Function composite
utilized in this study was moderately to highly with all other domains of cognitive
function including the Similarities subtest which loads significantly across all domains
(Table 3.2; Elias et al., 2006). Although many validated models of cognitive ability
incorporate the construct of a general cognitive ability whereby many faculties are
positively associated (i.e., G-factor), meta-analyses of hundreds of factor analytic
studies support the conceptual distinction between fluid (i.e., novel problem solving) and
crystalized (i.e., long-term memory/overlearned) abilities (Carroll, 1993; McArdle &
Hofer, 2014) despite considerable overlap. However, the distinction between general
fluid ability and Executive Function is less clear and there is no established standard for
what constitutes an Executive Function task versus a task of general fluid ability.
Others have observed that a single factor structure represents a better model fit than a
two-factor structure when applying statistical models to fluid ability subtests within the
Woodcock-Johnson Tests of Cognitive Abilities (i.e., Analysis Synthesis, Concept
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Formation, and Verbal Analogies) and individual tasks designed to measure aspects of
Executive Function (i.e., Category Test, Trail Making Test-B, Wisconsin Card Sorting
Test; Decker, Hill, & Dean, 2007). Although there is evidence for the incremental
predictive power of Executive Function in maintaining activities of daily living over global
cognitive ability, it is quite possible that disruption of any associated Executive/fluid
ability is likely to also be associated with general cognitive decline (J. K. Johnson et al.,
2007; Zheng et al., 2012). This may indicate that although Executive Function
impairment is a central symptom of the depression executive dysfunction
syndrome/vascular depression hypothesis, general cognitive impairment/decline
represents a common symptom among those with high levels of depressive symptoms
and lowered Executive Function (Alexopoulos et al., 2002).
Lastly, it is possible that lack of specificity of the associations of Executive
Function and symptoms of depression compared with other domains of cognitive
performance are due in part to the content of our chosen measure of depressive
symptoms. The Zung Depression Inventory has been shown to be a reliable and valid
measure of general depressive symptoms (Thurber, Snow, & Honts, 2002). However,
there is some evidence that individuals with Executive Function deficits, and poor
vascular profiles are more likely to exhibit a particular profile of depressive symptoms
which includes higher psychomotor retardation, and less severe expressions of guilt,
symptom insight, and agitation compared to depressed individuals without a poor
vascular profile/Executive Function profile (Alexopoulos et al., 2002; Hajjar et al., 2009;
Sobreiro et al., 2014). The focus of this study and of much of the literature (Hammar &
Ardal, 2009) on the associations of cognitive performance with a wide aggregated array
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of depressive symptoms, rather than a specific subset of symptoms associated more
with vascular depression may explain why Executive Function failed to distinguish itself
from other domains of cognitive function.
4.7 Mechanisms of Change
Our results relating to the Framingham Risk Score are consistent with prior
cross-sectional and longitudinal analyses which have found that those with healthier
cardiovascular profiles (i.e., Cardiovascular Health Score; Crichton et al., 2014; Reis et
al., 2013) are likelier to have higher cognitive performance across a range of domains
rather than within a specific area of functioning such as Executive Function.
Additionally, although we did not observe consistent cognitive performance mediation
for the associations of CVD-RF’s and changes in symptoms of depression, we did
observe a generalized independent predictor role of cognitive performance for changes
in symptoms. As such, although many studies exploring the vascular depression
hypothesis implicate the importance of Executive Function in maintaining activities of
daily living and emotional regulation, it is quite possible that cerebrovascular
mechanisms underlying these relationships may implicate a more generalized role of
cognitive performance.
First, one of the issues in exploring the specificity of the role of Executive
Function is finding a universal definition for vascular depression. Some researchers
have focused on functional outcomes such as reduced Executive Function
performance/treatment response (depression executive dysfunction syndrome) and
others have focused on pathophysiology using neuroimaging techniques (Sneed,
Rindskopf, Steffens, Krishnan, & Roose, 2008). As previously mentioned, older adults
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with poor vascular health and depression tend to exhibit irregularities and decreased
volume of the prefrontal cortex which is implicated in Executive Function (Jurado &
Rosselli, 2007; W. D. Taylor, Aizenstein, & Alexopoulos, 2014). However, older adults
with poor vascular profiles are also at higher risk for lower hippocampal/total brain
volume and diffuse small vessel disease as evidenced by the presence of WMH in MRI
studies (Prins et al., 2005; Royle et al., 2013; Yamawaki et al., 2015). These specific
and global cerebrovascular pathologies are implicated not only in Executive Function,
but decline in various domains of function including Global performance, Processing
Speed, Visual-Spatial Reasoning, and Memory (Prins et al., 2005) in addition to risk for
the development of late-life depression (Firbank et al., 2004; Godin et al., 2008;
Herrmann, Le Masurier, & Ebmeier, 2007; van Sloten et al., 2015).
4.8 Limitations of the Current Study
The limitations of the current study should be noted: (a) Neither depressive
symptoms nor cognitive function were manipulated, limiting our ability to establish
causality. (b) Individuals who were not available at wave 7 had higher depressive
symptoms levels and tHcy, lower cognitive performance, and higher incidence of
diabetes mellitus, and previous depression diagnosis requiring treatment. This may
have diminished our ability to examine the full range of the associations of CVD-RF’s,
cognitive performance, and depressive symptoms. However, this is a common issue in
longitudinal studies and it is more likely that our results are a conservative estimate of
the strength of these associations among a health sample. (c) Depressive symptoms
were determined by self-report rather than by structured interview. Although this is
common in depression literature, it is possible that the inclusion of a structured interview
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in addition to self-report may have increased the predictive value of symptoms of
depression for clinical outcomes (Uher et al., 2012). (d) We did not have a sufficiently
large enough sample to determine the incremental risks associated with having two
APOE-E4 alleles compared with just one APOE-E4 allele. (e) This present study was
limited to a two-wave 5-year analysis as measurement of tHcy was not available before
wave 6 of the MSLS. This limited our ability to study possibly non-linear associations
over time. (f) Our sample was highly educated, which limited our ability to examine
education as a potentially protective factor and modifier of CVD-RF’s on symptoms of
depression. (g) In analyzing the associations of cognitive performance and a broad
array of depressive symptoms, we may have diminished our ability to determine the
specificity of the associations of symptom with Executive Function. (h) Our measure of
Executive Function included several subtests included in other MSLS fluid reasoning
composites and is not a pure measure of Executive Function. As such, it is difficult to
determine if our generalized findings are due to a true lack of differentiation between
Executive Function and other measures of Fluid Reasoning.
4.9 Strengths of the Current Study
This study has several strengths: (a) To our knowledge, this is the longest
duration cross-lagged panel design analysis of executive function and depressive
symptoms. (b) This is the also the first study to observe the reciprocal associations of
depressive symptoms and cognitive function across a wide range of cognitive abilities,
allowing us to assess the relative specificity and strength of associations of Executive
Function and symptoms of depression compared with other domains of cognitive
function. (c) Our measure of Executive Function and other domains of cognitive
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function were composed of several subtests and were validated from previous factor
analyses on the MSLS battery (Elias et al., 2006). (d) The current study adjusted for
several demographic and CVD-RF variables and we were able to account for previous
depression diagnosis. (e) Cognitive performance and depressive symptoms were
measured continuously, increasing our ability to observe subtle variations in function.
(f) This is the first longitudinal analysis to consider the conditional mediation effect of
homocysteine (moderated by age and APOE-E4 status) on depressive symptoms
through Executive function and other domains of cognitive function. (g) JohnsonNeyman analyses conducted as part of this study allowed us to analyze the continuous
moderating effect of age on the associations of homocysteine and changes in
symptoms of depression rather than relying on arbitrary cut points. (h) In preliminary
analysis, we were able to determine that prior depression diagnosis requiring treatment
did not affect current levels of cognitive performance, extending the scope of our
unidirectional CLPD findings.
4.10 Future Directions
This longitudinal study extends the vascular depression hypothesis literature in
showing that those with lower cognitive performance and poor vascular profiles are at
an increased risk for symptoms of depression. Additionally, we observed increased
depressive symptoms among younger and middle-aged APOE-E4 carriers as a function
of tHcy, while this risk was delayed until later adulthood for non-carriers. Though the
results of this study and others represent a burgeoning evidence base for the validity of
the vascular depression hypothesis, more research is needed to extend these findings.
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First, many clinical profiles of vascular depression among older adults include
gait impairment/slowing. Many studies have shown that impaired gait function/speed
and falls among older adults (associated with Executive Function) may be a behavioral
marker for cerebrovascular insult (Amboni, Barone, & Hausdorff, 2013; Elias, Dore,
Davey, Robbins, & Elias, 2010; Pinheiro et al., 2014; Rubenstein, 2006). Although we
did have behavioral gait speed tests available in wave 6 and wave 7, dual task
paradigms (e.g., walking and verbal call and response) have been shown to have
consistently stronger associations with cognitive function and aspects of Executive
Function (i.e., attention, inhibition, working memory; Amboni et al., 2013; Holtzer, Wang,
& Verghese, 2012). Additionally, a recent randomized clinical trial has shown that older
adults enrolled into a 12-week aerobic exercise group experience increases in
Executive Function task performance and in addition to gait speed compared with a
control group (Falbo, Condello, Capranica, Forte, & Pesce, 2016). Future clinical trials
need to be conducted to determine whether these increases in dual task performance
as a function of aerobic exercise may also predict improvements in symptoms of
depression. A study of this design would support prior trials which have found aerobic
exercise to be an effective treatment for depressive symptoms among both younger and
older adults (Duman, Schlesinger, Russell, & Duman, 2008; Mura & Carta, 2013;
Strawbridge, Deleger, Roberts, & Kaplan, 2002).
Second, it is possible that the associations of depressive symptoms, cognitive
function, and CVD-RF’s are non-linear. As such, these associations may have been
masked or attenuated by the relatively healthy profile of our community sample. Prior
MSLS studies have shown that the cognitive risks associated with APOE-E4 genotype
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are most robust in the presence of diagnosed CVD (i.e., diabetes; Dore, Elias, Robbins,
Elias, & Nagy, 2009). Additionally, the associations between CVD-RF’s and symptoms
of depression may increase in strength as individuals approach resultant physical
disability and inability to carry out activities of daily living. Although high levels of
depressive symptoms increase risk for dependence and disengagement from leisure
activities for older adults, it is quite possible that institutional living itself may increase
risk for depressive symptoms and physical disability (McDougall et al., 2007).
Longitudinal studies are needed to determine the strength and directionality of
associations of institutional transition, CVD progression and symptoms of depression.
Third, the focus of this study was on the longitudinal associations of cognitive
performance and a broad range of depressive symptoms. As mentioned earlier, this
may have reduced our ability to determine the specificity of the relationships between
subsets of symptoms and Executive Function. Although we found that Executive
Function was broadly associated with symptoms of depression, exploring the
bidirectional associations of Executive Function with items relating to psychomotor
retardation, apathy, and loss of energy may reveal a more central role of Executive
Function in the development of depressive symptoms. Another path to exploring the
vascular depression subtype may be in conducting latent class analyses with subset
measures of depressive symptoms and Executive Function performance. Four factor
structures have been observed in both the ZDI and CES-D and it is possible that the
somatic/psychomotor retardation (CES-D and ZDI) and cognitive (ZDI) elements
identified by previous factor analyses (Edwards, Cheavens, Heiy, & Cukrowicz, 2010;
Romera, Delgado-Cohen, Perez, Caballero, & Gilaberte, 2008) may reveal specific
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associations with Executive Function. At this time, though a specific behavioral clinical
profile of the vascular depression subtype has yet to be fully established (Aizenstein et
al., 2016).
Lastly, the though our expanded measure of Executive Function was a significant
predictor of changes in depressive symptoms, the distinctions between what constitutes
an Executive Function vs. a fluid ability is unclear given their conceptual and statistical
overlaps (see Section 4.6). This in turn makes the incremental value of Executive
Function over other related tests of fluid ability unclear with respect to predicting
changes in depressive symptoms. These distinctions may be possible to determine in
future analyses after observing the strength of associations of Executive Function and
depressive symptoms after adjustment for general fluid ability. It is possible that after
adjusting for fluid ability, there are no unique associations between depressive
symptoms and Executive Function as we have defined it in this study.
4.11 Implications for Clinical Practice
The results of this study have direct implications for clinical practice. As the
percentage of U.S adults in middle and older adulthood increases, more individuals will
be at risk for cognitive decline and reduction of activities of daily living through
cerebrovascular insult. Our analyses in Tables 3.3 and 3.5 indicate that every 1standard deviation decrease in Executive Function corresponds with an approximate
0.15-standard deviation higher Zung Depression Inventory score and 0.10-standard
deviation increase in symptom levels over a 5-year period. Although on the individual
level, these effects are relatively modest, on the population level even modest
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reductions of the risks associated with depressive symptoms have important
epidemiological implications.
Thus far, short-term clinical trials have been ineffective in reducing cognitive
decline by way of tHcy-lowering diets with supplementation of B-vitamins among older
adults, though trials of ≥ 3 years have shown to be effective in reducing stroke events
(Clarke et al., 2014; Ji et al., 2013; Smith, 2008). It is possible that by later adulthood,
the benefits of supplementation on cognitive health by reducing tHcy may have
diminishing returns as tHcy-related cerebrovascular pathology may be cumulative over
the adult lifespan. Future long-term clinical trials are needed with younger populations
of adults to determine if tHcy reduction at earlier stages of life may be an effective
preventative measure for reducing cognitive decline.
Although the literature for B-vitamin supplementation for depressive symptoms
reduction is scarce, early evidence is promising. A Cochrane review of three
randomized clinical trials (treatment 2 – 6 months duration) has shown B-vitamin
supplementation among folate-deficient adults may be effective in further reducing
depressive symptoms in combination with psychotropic medication (i.e., trazodone and
fluoxetine). However, it is unclear whether folate supplementation may be a viable
substitute for psychotropic medications or if folate deficiency is a necessary condition
for symptom improvement (M. J. Taylor, Carney, Goodwin, & Geddes, 2004). It also
remains to be seen whether the effects of these short-term folate supplementation trials
were dependent upon reducing tHcy or CVD-RF profile. It is also entirely possible that
benefits of folate supplementation on depressive symptoms reduction are a result of
tHcy’s conversion to S-adenosyl-methionine which regulates serotonin metabolism
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(Ganguly & Alam, 2015; Refsum et al., 2004). Long-term clinical trials are needed to
determine the specific mechanisms of B-vitamin supplementation on depressive
symptoms.
Although supplementation trials have produced somewhat mixed results,
increasing exercise and physical activity has been shown to not only be an effective
preventive measure among healthy patients in maintenance of cognitive health and
emotion regulation, but also as a treatment for clinical levels of cognitive impairment
and symptoms of depression (Churchill et al., 2002; Mura & Carta, 2013). Higher levels
of physical activity may also prevent all-cause dementia independent of APOE-E4
status (Podewils et al., 2005). Regular aerobic activity has been associated with lower
tHcy in addition to improvements among several clinical markers of cerebrovascular
health including lower LDL, triglycerides, blood pressure, and higher HDL, glucose
sensitivity, cerebral blood flow, and levels of brain-derived neurotropic factor (Crichton
et al., 2014; Duman et al., 2008; Okura et al., 2006; Yoshida et al., 2010). Lastly,
inclusion of self-report items about physical activity and exercise to primary care
questionnaires may increase the predictive value of Framingham Risk Scores in
determining 10-year risk of CHD (Arsenault et al., 2010). Although the exact
mechanisms for the cognitive/affective benefits of regular physical activity and aerobic
exercise may be many-fold and unclear at this time, the possibility of reducing the social
burdens associated of any or all of these risks has far-reaching public health
implications.
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APPENDIX A
Zung Depression Inventory
Table A1 List of Zung Depression Inventory Items

Number

Item

Reverse-Scored

1.

I feel down-hearted and blue

2.

Morning is when I feel the best

3.

I have crying spells or feel like it

4.

I have trouble sleeping at night

5.

I eat as much as I used to

X

6.

I still enjoy sex

X

7.

I notice that I am losing weight

8.

I have trouble with constipation

9.

My heart beats faster than usual

10.

I get tired for no reason

11.

My mind is as clear as it used to be

X

12.

I find is easy to do the things I used to

X

13.

I am restless and can’t keep still

14

I feel hopeful about the future

15.

I am more irritable than usual

16.

I find it easy to make decisions

X

17.

I feel that I am useful and needed

X

18.

My life is pretty full

X

19.

I feel that others would be better off if I
were dead

20.

I still enjoy the things I used to
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X

X

X

APPENDIX B
Framingham Risk Score Weights
Table B1. Framingham Risk Score for Men
Age

Points

Total
Cholesterol

Points

Point
Total

10-Year
Risk

20-34

0

<160

0

≤ -3

<1%

35-39

2

160-199

1

-2

1.1%

40-44

5

200-239

2

-1

1.4%

45-49

6

240-279

3

0

1.6%

50-54

8

280+

4

1

1.9%

55-59

10

2

2.3%

60-64

11

Systolic BP

If
Untreated

If
Treated

3

2.8%

65-69

12

<120

-2

0

4

3.3%

70-74

14

120-129

0

2

5

3.9%

75-79

15

130-139

1

3

6

4.7%

140-149

2

4

7

5.6%

150-159

2

4

8

6.7%

160+

3

5

9

7.9%

10

9.4%

Smoking
Status

Points

HDL

Points

11

11.2%

Nonsmoker

0

60+

-2

12

13.3%

Smoker

4

50-59

-1

13

15.6%

40-49

0

14

18.4%

Diabetes
Status

Points

35-44

1

15

21.6%

Diabetic

0

≤34

2

16

25.3%

NonDiabetic

3

17

29.4%

18 or
more

> 30%

Desk reference: National Heart Lung, and Blood Institute
http://www.ccs.ca/images/Guidelines/Tools_and_Calculators_En/Lipids_Gui_2012_FRS_BW_E
N.pdf
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Table B2. Framingham Risk Score for Women
Age

Points

Total
Cholesterol

Points

Point
Total

10-Year
Risk

20-34

0

<160

0

≤ -3

<1%

35-39

2

160-199

1

-2

<1%

40-44

4

200-239

3

-1

1.0%

45-49

5

240-279

4

0

1.2%

50-54

7

280+

5

1

1.5%

55-59

8

2

1.7%

3

2.0%

4

2.4%

60-64

9

Systolic BP

65-69

10

<120

If
Untreated
-3

If
Treated
-1

70-74

11

120-129

0

2

5

2.8%

75-79

12

130-139

1

3

6

3.3%

140-149

2

5

7

3.9%

150-159

4

6

8

4.5%

160+

5

7

9

5.3%

10

6.3%

Smoking
Status

Points

HDL

Points

11

7.3%

Nonsmoker

0

60+

-2

12

8.6%

Smoker

4

50-59

-1

13

10.0%

40-49

0

14

11.7%

Diabetes
Status

Points

35-44

1

15

13.7%

Diabetic

0

≤34

2

16

15.9%

NonDiabetic

3

17

18.5%

18

21.5%

19

24.8%

20

27.5%

21 or
more

> 30%

Desk reference: National Heart Lung, and Blood Institute
http://www.ccs.ca/images/Guidelines/Tools_and_Calculators_En/Lipids_Gui_2012_FRS_BW_E
N.pdf
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APPENDIX C
Theoretically Relevant Covariates
Table C1. Cross-Sectional and Prospective Studies of Homocysteine and Symptoms of Depression
Authors, date

Design

Age,
Gender

Covariates

Results
high Hcy predicted higher
likelihood for elevated
depressive symptoms
high Hcy associated with
elevated depressive
symptoms/Dx., but not after
adjustment for functional
disability and CVD
high Hcy unrelated to
elevated depressive
symptoms.

(Gu et al.,
2012)

crosssectional

20-90y, M/F

age, sex, BMI, exercise, education, smoking, antidepressant use, creatinine level,
alcohol use, and chronic medical conditions

(Tiemeier et
al., 2002b)

crosssectional

≥55y, M/F

age, sex, cardiovascular disease, and functional disability

(Ng, Feng et
al., 2009)

crosssectional

≥55y, M/F 

(Nanri et al.,
2010)

crosssectional

21-67y, M/F

unadjusted and adjusted for age, housing size, education, social network and
support, smoking, alcohol, underweight, obesity, antidepressant use, depressioninducing drugs, number of medical comorbidities, disability, unintended weight
gain/loss, supplements, anemia, albumin, and creatinine
age, site, job position, marital status, occupational physical activity, leisure-time
physical activity, smoking and alcohol use

(Almeida et
al., 2008)

crosssectional

≥65y, M

age, education, living arrangements, smoking, alcohol use, physical activity, and
number of medical comorbidities

(Tolmunen et
al., 2004)

crosssectional/4.0year incident

46-64, M

month of study, ischemic heart disease, smoking, alcohol use, marital status,
education, and socioeconomic status (secondary exclusion of CVD)

(Forti et al.,
2010)

prospective,
3.9-year
follow-up

≥65y, M/F

Exclusion control for high depressive symptoms and adjustment for education,
CVD, hypertension, stroke, diabetes, chronic pulmonary disease, and cancer,
ADL disability

(Kim et al.,
2008)

prospective,
2.4-year
follow-up

≥65y, M/F

age, sex, education, MMSE, disability, smoking, alcohol, sedentary status,
vascular risk score, serum creatinine
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high Hcy associated with
elevated depressive
symptoms among men
(trend p = .06), but not
among women
high Hcy associated with
elevated depressive
symptoms
baseline Hcy associated
with baseline and incident
elevations in depressive
symptoms
highest homocysteine
tertile associated with
incident depression among
women, but not in men
baseline and increase in
Hcy level associated with
incident depression at
follow-up

Table C2. Cross-Sectional and Prospective studies of Homocysteine and Cognitive function
Authors, date

Design

Age,
Gender

Covariates

(Polito et al.,
2016)

crosssectional

72-77y, M/F

age, sex, education, CVD, stroke, diabetes, high cholesterol, folic acid, systolic
BP, APOE-ε4/ MTHFR, 5,10 methylenetetrahydrofolate reductase genotype

(Moorthy et
al., 2012)

crosssectional

45-103y

age, sex, ethnicity, and education as well as Apo-ε4 genotype, plasma folate,
plasma B-12 and B-6, kidney function, and presence of diabetes and
hypertension

(Elias et al.,
2005)

crosssectional

40-82

Framingham Stroke risk profile (age, systolic blood pressure, antihypertensive
medication, diabetes, cigarette smoking status, cardiovascular disease, left
ventricular hypertrophy, and atrial fibrillation), diabetes, creatinine, total
cholesterol, BMI, alcohol intake, coffee intake, APOE-ε4 genotype, plasma B-12,
B9 and B6

(Elias et al.,
2008)

crosssectional

(Bonetti,
Brombo,
Magon, &
Zuliani, 2015)
(Feng, Ng,
Chuah, Niti, &
Kua, 2006)

crosssectional

≥65y, M/F

age, sex, education, stroke history, cerebral atrophy (cerebral tomography), and
plasma B-12

crosssectional

≥65y, M/F

age, sex, and number of years of education, cigarette smoking, alcohol
consumption, BMI, total cholesterol, hypertension, diabetes,
cardiovascular disease, creatinine, depressive symptoms, plasma B-9 and B-12

(Nurk et al.,
2005)

prospective,
6-year
follow-up

65-67y, M/F

sex, education, CVD, depression, baseline tHcy, and APOE-ε4 genotype

(Zylberstein et
al., 2011)

Prospective,
22-year
follow-up

38-60, F

age, education, BMI, cholesterol, triglycerides, systolic and diastolic BP, smoking,
creatinine, and plasma B12.

age, sex, education, CVD, plasma B-12 and B-6

112

Results
Hcy and APOE-ε4 genotype
inversely associated with
executive function, but not
memory
low plasma B-vitamins and
APOE-ε4 genotype inversely
associated with MMSE score
and positively associated
with depressive symptoms
significant interactions
between age and Hcy.
Associations were found
between higher Hcy among
adults ≥60y and reduced
global cognitive performance
Hcy inversely associated
with global cognitive
performance, MMSE,
working memory, trend for
similarities. Significant
interaction of APOE-ε4
status on performance.
hyperhomocysteinemia
associated with highest risk
for dementia Dx. and
functional impairment.
higher Hcy was inversely
associated with processing
speed and constructional
ability (Block Design)
increased Hcy was
associated with lower
episodic memory
performance
highest tertile Hcy
associated with higher risk
for dementia and AD

APPENDIX D
Cross-Lagged Panel Analyses of other Cognitive Domains
Figure D1. Cross-Lagged Panel Analysis for Working Memory

***p<.001, **p<.01, *p<.05 +p<.10
ST = Working Memory
ZDI = Zung Depression Inventory
Fit Indices
RMSE = 0.060
χ2(70) = 248.316, p < .001
χ2/df = 3.547
CFI = 0.954
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Figure D2. Cross-Lagged Panel Analysis for Global composite

***p<.001, **p<.01, *p<.05 +p<.10
ST = Scanning and Tracking
ZDI = Zung Depression Inventory
Fit Indices
RMSE = 0.077
χ2(882) = 4648.440, p < .001
χ2/df = 5.270
CFI = 0.816
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Figure D3. Cross-Lagged Panel Analysis for Visual-Spatial Organization and Memory

***p<.001, **p<.01, *p<.05 +p<.10
VSOM = Visual-Spatial Organization and Memory
ZDI = Zung Depression Inventory
Fit Indices
RMSE = 0.066
χ2(138) = 573.539, p < .001
χ2/df = 4.156
CFI = 0.940
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Figure D4. Cross-Lagged Panel Analysis for Scanning and Tracking

***p<.001, **p<.01, *p<.05 +p<.10
ST = Scanning and Tracking
ZDI = Zung Depression Inventory
Fit Indices
RMSE = 0.044
χ2(70) = 167.777, p < .001
χ2/df = 2.397
CFI = 0.984
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Figure D5. Cross-Lagged Panel Analysis for Verbal Episodic Memory

***p<.001, **p<.01, *p<.05 +p<.10
VEM = Verbal Episodic Memory
ZDI = Zung Depression Inventory
Fit Indices
RMSE = 0.076
χ2(42) = 216.637, p < .001
χ2/df = 5.158
CFI = 0.96
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